JP2022538773A - 高分子支持アミノベンズアピン化合物 - Google Patents
高分子支持アミノベンズアピン化合物 Download PDFInfo
- Publication number
- JP2022538773A JP2022538773A JP2021573551A JP2021573551A JP2022538773A JP 2022538773 A JP2022538773 A JP 2022538773A JP 2021573551 A JP2021573551 A JP 2021573551A JP 2021573551 A JP2021573551 A JP 2021573551A JP 2022538773 A JP2022538773 A JP 2022538773A
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- polymeric support
- compound
- mmol
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 232
- 239000000203 mixture Substances 0.000 claims abstract description 316
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 107
- 201000011510 cancer Diseases 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 71
- QXUNLRUYUXSFQE-UHFFFAOYSA-N 1h-1-benzazepin-2-amine Chemical class N1C(N)=CC=CC2=CC=CC=C21 QXUNLRUYUXSFQE-UHFFFAOYSA-N 0.000 claims abstract description 41
- 125000005647 linker group Chemical group 0.000 claims abstract description 32
- 230000021615 conjugation Effects 0.000 claims abstract description 16
- 125000000524 functional group Chemical group 0.000 claims abstract description 14
- -1 proline amino acid Chemical class 0.000 claims description 151
- 150000001413 amino acids Chemical group 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 43
- 125000001072 heteroaryl group Chemical group 0.000 claims description 42
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 102000002689 Toll-like receptor Human genes 0.000 claims description 32
- 108020000411 Toll-like receptor Proteins 0.000 claims description 32
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 30
- 239000000460 chlorine Substances 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 19
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 18
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 16
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 229920001222 biopolymer Polymers 0.000 claims description 11
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 10
- 239000002105 nanoparticle Substances 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 9
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 8
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 8
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 6
- 229910004013 NO 2 Inorganic materials 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 150000003568 thioethers Chemical class 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- 230000007112 pro inflammatory response Effects 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 230000008484 agonism Effects 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 2
- 125000003473 lipid group Chemical group 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 292
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 275
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 176
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 150
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 144
- 230000015572 biosynthetic process Effects 0.000 description 133
- 238000003786 synthesis reaction Methods 0.000 description 133
- 238000006243 chemical reaction Methods 0.000 description 122
- 235000019439 ethyl acetate Nutrition 0.000 description 106
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 105
- 239000007787 solid Substances 0.000 description 95
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 94
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 91
- 238000004519 manufacturing process Methods 0.000 description 91
- 229920001223 polyethylene glycol Polymers 0.000 description 79
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 77
- 239000000243 solution Substances 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 63
- 239000012071 phase Substances 0.000 description 60
- 238000002953 preparative HPLC Methods 0.000 description 60
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 57
- 239000012267 brine Substances 0.000 description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 49
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 49
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 48
- 239000003208 petroleum Substances 0.000 description 44
- 239000002245 particle Substances 0.000 description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 40
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 40
- 239000003921 oil Substances 0.000 description 40
- 229910052938 sodium sulfate Inorganic materials 0.000 description 40
- 235000011152 sodium sulphate Nutrition 0.000 description 40
- 239000007832 Na2SO4 Substances 0.000 description 39
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 37
- 239000011541 reaction mixture Substances 0.000 description 37
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 35
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 33
- 238000010898 silica gel chromatography Methods 0.000 description 33
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 31
- 239000012044 organic layer Substances 0.000 description 31
- 238000004128 high performance liquid chromatography Methods 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 29
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 239000003814 drug Substances 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 239000008346 aqueous phase Substances 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 24
- 239000011734 sodium Substances 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 19
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 19
- 239000012230 colorless oil Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000002671 adjuvant Substances 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 17
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 15
- 239000000562 conjugate Substances 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- SPACBXGCBXVBGM-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)O)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)O)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO SPACBXGCBXVBGM-UHFFFAOYSA-N 0.000 description 14
- 229910004298 SiO 2 Inorganic materials 0.000 description 14
- 239000005457 ice water Substances 0.000 description 14
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 14
- 238000004809 thin layer chromatography Methods 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- 239000007821 HATU Substances 0.000 description 13
- 230000027455 binding Effects 0.000 description 13
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 206010025323 Lymphomas Diseases 0.000 description 10
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- PBYIIRLNRCVTMQ-UHFFFAOYSA-N 2,3,5,6-tetrafluorophenol Chemical compound OC1=C(F)C(F)=CC(F)=C1F PBYIIRLNRCVTMQ-UHFFFAOYSA-N 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 241000209094 Oryza Species 0.000 description 8
- 235000007164 Oryza sativa Nutrition 0.000 description 8
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 235000009566 rice Nutrition 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 6
- 208000017604 Hodgkin disease Diseases 0.000 description 6
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 150000005829 chemical entities Chemical class 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229940127121 immunoconjugate Drugs 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 6
- 208000029974 neurofibrosarcoma Diseases 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 235000015320 potassium carbonate Nutrition 0.000 description 6
- 238000012746 preparative thin layer chromatography Methods 0.000 description 6
- 235000019260 propionic acid Nutrition 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 5
- 239000012346 acetyl chloride Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 201000010536 head and neck cancer Diseases 0.000 description 5
- 208000014829 head and neck neoplasm Diseases 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 5
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 5
- YMXIIVIQLHYKOT-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical group O1C(C)(C)C(C)(C)OB1C1=CC=CC(N)=C1 YMXIIVIQLHYKOT-UHFFFAOYSA-N 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 4
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 4
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 4
- KLONZNNRVYTGNO-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO KLONZNNRVYTGNO-UHFFFAOYSA-N 0.000 description 4
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 4
- 229940124614 TLR 8 agonist Drugs 0.000 description 4
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 4
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 4
- NARMWQXCVLHRIM-UHFFFAOYSA-N [1-(3-bromophenyl)sulfonylazetidin-3-yl]methanol Chemical compound C1C(CO)CN1S(=O)(=O)C1=CC=CC(Br)=C1 NARMWQXCVLHRIM-UHFFFAOYSA-N 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- GNVWVYIAQBJHGV-UHFFFAOYSA-N azetidin-3-ylmethanol Chemical compound OCC1CNC1 GNVWVYIAQBJHGV-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 4
- 238000011033 desalting Methods 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 206010024627 liposarcoma Diseases 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- AKBICEUTJHZUEV-UHFFFAOYSA-N tert-butyl n-[3-(propylamino)propyl]carbamate Chemical compound CCCNCCCNC(=O)OC(C)(C)C AKBICEUTJHZUEV-UHFFFAOYSA-N 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- PJGOLCXVWIYXRQ-UHFFFAOYSA-N 3-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(Br)=C1 PJGOLCXVWIYXRQ-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- KHPUVMAHWIDNLJ-UHFFFAOYSA-N 5h-1-benzazepine-4-carboxamide Chemical compound C1C(C(=O)N)=CC=NC2=CC=CC=C21 KHPUVMAHWIDNLJ-UHFFFAOYSA-N 0.000 description 3
- SIWYQJLYLJPWHW-UHFFFAOYSA-N BrC=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CNC(OC(C)(C)C)=O Chemical compound BrC=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CNC(OC(C)(C)C)=O SIWYQJLYLJPWHW-UHFFFAOYSA-N 0.000 description 3
- UFHVQKMPCPNYDX-UHFFFAOYSA-N C(C1=CC=CC=C1)N(CCCCCNC(OC(C)(C)C)=O)CCC Chemical compound C(C1=CC=CC=C1)N(CCCCCNC(OC(C)(C)C)=O)CCC UFHVQKMPCPNYDX-UHFFFAOYSA-N 0.000 description 3
- DUMNONGLJXPBSF-UHFFFAOYSA-N C(C1=CC=CC=C1)N(CCCNC(OC(C)(C)C)=O)CCC Chemical compound C(C1=CC=CC=C1)N(CCCNC(OC(C)(C)C)=O)CCC DUMNONGLJXPBSF-UHFFFAOYSA-N 0.000 description 3
- IOIUXWTVVSNQEW-UHFFFAOYSA-N C1=C(C(O)=O)CC(N)=NC2=CC(Br)=CC=C21 Chemical compound C1=C(C(O)=O)CC(N)=NC2=CC(Br)=CC=C21 IOIUXWTVVSNQEW-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 3
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010066948 Myxofibrosarcoma Diseases 0.000 description 3
- ZJZCJSUXTUTEQP-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(N(CCC)CCCNC(=O)OC(C)(C)C)=O)C=CC(=C2)C(=O)O Chemical compound NC1=NC2=C(C=C(C1)C(N(CCC)CCCNC(=O)OC(C)(C)C)=O)C=CC(=C2)C(=O)O ZJZCJSUXTUTEQP-UHFFFAOYSA-N 0.000 description 3
- ZBPCFEXXYFLRAJ-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2)Br)C(=O)N(CCC)CCCNC(OC(C)(C)C)=O Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2)Br)C(=O)N(CCC)CCCNC(OC(C)(C)C)=O ZBPCFEXXYFLRAJ-UHFFFAOYSA-N 0.000 description 3
- RKQGDHSAEREOMC-UHFFFAOYSA-N NCCNC(=O)C1CCN(CC1)C1=NC=C(C=C1)[N+](=O)[O-] Chemical compound NCCNC(=O)C1CCN(CC1)C1=NC=C(C=C1)[N+](=O)[O-] RKQGDHSAEREOMC-UHFFFAOYSA-N 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- AKPCZBCWTFVJKR-UHFFFAOYSA-N [1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]sulfonylazetidin-3-yl]methanol Chemical compound CC1(OB(OC1(C)C)C=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CO)C AKPCZBCWTFVJKR-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 150000001371 alpha-amino acids Chemical class 0.000 description 3
- 235000008206 alpha-amino acids Nutrition 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 239000013385 inorganic framework Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000867 larynx Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006308 propyl amino group Chemical group 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 206010042863 synovial sarcoma Diseases 0.000 description 3
- NJTCJQSNTOXUPM-UHFFFAOYSA-N tert-butyl N-[5-(propylamino)pentyl]carbamate Chemical compound CCCNCCCCCNC(=O)OC(C)(C)C NJTCJQSNTOXUPM-UHFFFAOYSA-N 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- XASAPYQVQBKMIN-UHFFFAOYSA-K ytterbium(iii) fluoride Chemical compound F[Yb](F)F XASAPYQVQBKMIN-UHFFFAOYSA-K 0.000 description 3
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 2
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 2
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- ZFXVFMBOFIEPII-UHFFFAOYSA-N 1h-azepine-4-carboxamide Chemical compound NC(=O)C1=CC=CNC=C1 ZFXVFMBOFIEPII-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- ANETXMNWGGUXLC-UHFFFAOYSA-N 2-benzylsulfanyl-4-bromobenzonitrile Chemical compound C(C1=CC=CC=C1)SC1=C(C#N)C=CC(=C1)Br ANETXMNWGGUXLC-UHFFFAOYSA-N 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- NZHPVPMRNASEQK-UHFFFAOYSA-N 3-isocyanatobenzonitrile Chemical compound O=C=NC1=CC=CC(C#N)=C1 NZHPVPMRNASEQK-UHFFFAOYSA-N 0.000 description 2
- UXCYPHCFQAFVFH-UHFFFAOYSA-N 3-isothiocyanatobenzonitrile Chemical compound S=C=NC1=CC=CC(C#N)=C1 UXCYPHCFQAFVFH-UHFFFAOYSA-N 0.000 description 2
- AIUMSXRDEJJHPG-UHFFFAOYSA-N 3h-1-benzazepine-4-carboxamide Chemical compound N1=CCC(C(=O)N)=CC2=CC=CC=C21 AIUMSXRDEJJHPG-UHFFFAOYSA-N 0.000 description 2
- NBZGZEXKBNJIFV-UHFFFAOYSA-N 4-bromo-2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]azetidin-1-yl]sulfonylbenzonitrile Chemical compound BrC1=CC(=C(C#N)C=C1)S(=O)(=O)N1CC(C1)CO[Si](C)(C)C(C)(C)C NBZGZEXKBNJIFV-UHFFFAOYSA-N 0.000 description 2
- SOKKWUDFSPLQCO-UHFFFAOYSA-N 4-bromo-2-iodo-6-nitrobenzaldehyde Chemical compound [O-][N+](=O)c1cc(Br)cc(I)c1C=O SOKKWUDFSPLQCO-UHFFFAOYSA-N 0.000 description 2
- XLWQUESMILVIPR-UHFFFAOYSA-N 4-ethoxybenzoyl chloride Chemical compound CCOC1=CC=C(C(Cl)=O)C=C1 XLWQUESMILVIPR-UHFFFAOYSA-N 0.000 description 2
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 2
- DJUBNZOEBVGNEZ-UHFFFAOYSA-N 5-bromo-1-iodo-2-methyl-3-nitrobenzene Chemical compound CC1=C(I)C=C(Br)C=C1[N+]([O-])=O DJUBNZOEBVGNEZ-UHFFFAOYSA-N 0.000 description 2
- BPGQSAVORPJKIJ-UHFFFAOYSA-N 5-bromo-2-cyanobenzenesulfonyl chloride Chemical compound BrC=1C=CC(=C(C=1)S(=O)(=O)Cl)C#N BPGQSAVORPJKIJ-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FRDJBHKLHHVXHY-UHFFFAOYSA-N BrC1=CC(=C(C#N)C=C1)S(=O)(=O)N1CC(C1)CO Chemical compound BrC1=CC(=C(C#N)C=C1)S(=O)(=O)N1CC(C1)CO FRDJBHKLHHVXHY-UHFFFAOYSA-N 0.000 description 2
- ZYQSNLJSHITYSI-UHFFFAOYSA-N BrC=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CN Chemical compound BrC=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CN ZYQSNLJSHITYSI-UHFFFAOYSA-N 0.000 description 2
- WSSDLIDUWPOUNN-UHFFFAOYSA-N BrC=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CN(C)C Chemical compound BrC=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CN(C)C WSSDLIDUWPOUNN-UHFFFAOYSA-N 0.000 description 2
- CLJQMNLFVLIUGF-UHFFFAOYSA-N BrC=1C=C(CN(C(OC(C)(C)C)=O)C)C=C(C=1)Br Chemical compound BrC=1C=C(CN(C(OC(C)(C)C)=O)C)C=C(C=1)Br CLJQMNLFVLIUGF-UHFFFAOYSA-N 0.000 description 2
- VJSDTESXVBHYDA-UHFFFAOYSA-N BrC=1C=C(CN(C(OC(C)(C)C)=O)C)C=C(C=1)S(=O)(=O)Cl Chemical compound BrC=1C=C(CN(C(OC(C)(C)C)=O)C)C=C(C=1)S(=O)(=O)Cl VJSDTESXVBHYDA-UHFFFAOYSA-N 0.000 description 2
- JEDJIBHXCIEAKZ-UHFFFAOYSA-N BrC=1C=C(CN(C(OC(C)(C)C)=O)C)C=C(C=1)S(=O)(=O)N1CC(C1)CO Chemical compound BrC=1C=C(CN(C(OC(C)(C)C)=O)C)C=C(C=1)S(=O)(=O)N1CC(C1)CO JEDJIBHXCIEAKZ-UHFFFAOYSA-N 0.000 description 2
- DUUFNBZSNIFOKS-UHFFFAOYSA-N C(#N)C=1C=C(C=CC=1)N=C=NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)OC(C)(C)C Chemical compound C(#N)C=1C=C(C=CC=1)N=C=NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)OC(C)(C)C DUUFNBZSNIFOKS-UHFFFAOYSA-N 0.000 description 2
- GBFAFMWJFKAUBO-UHFFFAOYSA-N C(C)(=O)NCCNC(=O)C1CCN(CC1)C1=NC=C(C=C1)N Chemical compound C(C)(=O)NCCNC(=O)C1CCN(CC1)C1=NC=C(C=C1)N GBFAFMWJFKAUBO-UHFFFAOYSA-N 0.000 description 2
- WJQFIVGBBQZGEQ-UHFFFAOYSA-N C(C)(=O)NCCNC(=O)C1CCN(CC1)C1=NC=C(C=C1)[N+](=O)[O-] Chemical compound C(C)(=O)NCCNC(=O)C1CCN(CC1)C1=NC=C(C=C1)[N+](=O)[O-] WJQFIVGBBQZGEQ-UHFFFAOYSA-N 0.000 description 2
- MBYSUESSIZPSOE-UHFFFAOYSA-N C(C1=CC=CC=C1)N(CCCN(C(OC(C)(C)C)=O)C)CCC Chemical compound C(C1=CC=CC=C1)N(CCCN(C(OC(C)(C)C)=O)C)CCC MBYSUESSIZPSOE-UHFFFAOYSA-N 0.000 description 2
- LWKJIYWUWRWFTH-UHFFFAOYSA-N C(C1=CC=CC=C1)N(CCCOCCCNC(OC(C)(C)C)=O)CCC Chemical compound C(C1=CC=CC=C1)N(CCCOCCCNC(OC(C)(C)C)=O)CCC LWKJIYWUWRWFTH-UHFFFAOYSA-N 0.000 description 2
- MGEFTSXAOMWBTC-UHFFFAOYSA-N C(C1=CC=CC=C1)N(CCNC(OC(C)(C)C)=O)CCC Chemical compound C(C1=CC=CC=C1)N(CCNC(OC(C)(C)C)=O)CCC MGEFTSXAOMWBTC-UHFFFAOYSA-N 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 2
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 229930195711 D-Serine Natural products 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 229930028154 D-arginine Natural products 0.000 description 2
- 229930182846 D-asparagine Natural products 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 229930182847 D-glutamic acid Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 2
- 229930195715 D-glutamine Natural products 0.000 description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 2
- 229930195721 D-histidine Natural products 0.000 description 2
- 229930182845 D-isoleucine Natural products 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 2
- 229930182818 D-methionine Natural products 0.000 description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 2
- 229930182832 D-phenylalanine Natural products 0.000 description 2
- 229930182820 D-proline Natural products 0.000 description 2
- 229930182827 D-tryptophan Natural products 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 2
- 229930195709 D-tyrosine Natural products 0.000 description 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 2
- 229930182831 D-valine Natural products 0.000 description 2
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 2
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 2
- 206010059352 Desmoid tumour Diseases 0.000 description 2
- 229930195710 D‐cysteine Natural products 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010024612 Lipoma Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- OBFGGGWREUUOMK-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CC#CCN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CC#CCN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO OBFGGGWREUUOMK-UHFFFAOYSA-N 0.000 description 2
- ORCYENYISRURBC-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CC1=CC=C(C=C1)CN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CC1=CC=C(C=C1)CN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO ORCYENYISRURBC-UHFFFAOYSA-N 0.000 description 2
- ORHQKSQFZNAPTQ-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO ORHQKSQFZNAPTQ-UHFFFAOYSA-N 0.000 description 2
- ISYOGKKQAWHQOZ-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)OCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)OCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO ISYOGKKQAWHQOZ-UHFFFAOYSA-N 0.000 description 2
- JARDDKCDABQSCR-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(N(CCC)CCCNC(=O)OC(C)(C)C)=O)C=CC(=C2)C(=O)OC Chemical compound NC1=NC2=C(C=C(C1)C(N(CCC)CCCNC(=O)OC(C)(C)C)=O)C=CC(=C2)C(=O)OC JARDDKCDABQSCR-UHFFFAOYSA-N 0.000 description 2
- BDRNOHWIUCXGEH-UHFFFAOYSA-N NC=1C=CC(=NC=1)N1CCC(CC1)C(=O)NCCNC(C(F)(F)F)=O Chemical compound NC=1C=CC(=NC=1)N1CCC(CC1)C(=O)NCCNC(C(F)(F)F)=O BDRNOHWIUCXGEH-UHFFFAOYSA-N 0.000 description 2
- DYIAAOCBDYXGFM-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2)Br)C(=O)N(CCC)CCCN(C(OC(C)(C)C)=O)C Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2)Br)C(=O)N(CCC)CCCN(C(OC(C)(C)C)=O)C DYIAAOCBDYXGFM-UHFFFAOYSA-N 0.000 description 2
- UTXBJYMZYCQNNW-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2)C(=O)NC1=CC=CC=C1)C(=O)N(CCC)CCCN Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2)C(=O)NC1=CC=CC=C1)C(=O)N(CCC)CCCN UTXBJYMZYCQNNW-UHFFFAOYSA-N 0.000 description 2
- PITNGSZAJWJGAJ-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2I)Br)C(=O)N(CCC)CCC Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2I)Br)C(=O)N(CCC)CCC PITNGSZAJWJGAJ-UHFFFAOYSA-N 0.000 description 2
- MOUYKQIIWDIWLC-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2I)Br)C(=O)OCC Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2I)Br)C(=O)OCC MOUYKQIIWDIWLC-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- WSOJXNBFIZGVIZ-UHFFFAOYSA-N [N+](=O)([O-])C=1C=CC(=NC=1)N1CCC(CC1)C(=O)NCCNC(C(F)(F)F)=O Chemical compound [N+](=O)([O-])C=1C=CC(=NC=1)N1CCC(CC1)C(=O)NCCNC(C(F)(F)F)=O WSOJXNBFIZGVIZ-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000002041 carbon nanotube Substances 0.000 description 2
- 229910021393 carbon nanotube Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001854 cinnolines Chemical class 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 150000001907 coumarones Chemical class 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 201000006827 desmoid tumor Diseases 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- CPBLDQHHAVXEED-VMPITWQZSA-N ethyl (E)-3-(4-bromo-2-iodo-6-nitrophenyl)-2-(cyanomethyl)prop-2-enoate Chemical compound BrC1=CC(=C(C(=C1)[N+](=O)[O-])/C=C(/C(=O)OCC)\CC#N)I CPBLDQHHAVXEED-VMPITWQZSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 102000045715 human TLR7 Human genes 0.000 description 2
- 102000045720 human TLR8 Human genes 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002082 metal nanoparticle Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 2
- DLMMQHNYEBTUFT-UHFFFAOYSA-N n-ethoxypropan-1-amine Chemical compound CCCNOCC DLMMQHNYEBTUFT-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003246 quinazolines Chemical class 0.000 description 2
- 150000003252 quinoxalines Chemical class 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229940074404 sodium succinate Drugs 0.000 description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- ULLGNVIMORYMTD-UHFFFAOYSA-N tert-butyl N-[[4-(propylaminomethyl)phenyl]methyl]carbamate Chemical compound C(CC)NCC1=CC=C(C=C1)CNC(OC(C)(C)C)=O ULLGNVIMORYMTD-UHFFFAOYSA-N 0.000 description 2
- BUAQLHONSYDRTG-UHFFFAOYSA-N tert-butyl N-[[4-bromo-2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]azetidin-1-yl]sulfonylphenyl]methyl]-N-methylcarbamate Chemical compound BrC1=CC(=C(C=C1)CN(C(OC(C)(C)C)=O)C)S(=O)(=O)N1CC(C1)CO[Si](C)(C)C(C)(C)C BUAQLHONSYDRTG-UHFFFAOYSA-N 0.000 description 2
- MOLUHRBHXXGWDP-UHFFFAOYSA-N tert-butyl n-(azetidin-3-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CNC1 MOLUHRBHXXGWDP-UHFFFAOYSA-N 0.000 description 2
- NYODQEVNDGLFRF-UHFFFAOYSA-N tert-butyl n-[2-(propylamino)ethyl]carbamate Chemical compound CCCNCCNC(=O)OC(C)(C)C NYODQEVNDGLFRF-UHFFFAOYSA-N 0.000 description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical compound C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 description 1
- BUTKUPGRCQCTTA-INIZCTEOSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-sulfopropanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CS(O)(=O)=O)C(=O)O)C3=CC=CC=C3C2=C1 BUTKUPGRCQCTTA-INIZCTEOSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RMXLHIUHKIVPAB-OWOJBTEDSA-N (e)-1,4-dibromobut-2-ene Chemical compound BrC\C=C\CBr RMXLHIUHKIVPAB-OWOJBTEDSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 150000003919 1,2,3-triazines Chemical class 0.000 description 1
- 150000003920 1,2,4-triazines Chemical class 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- 150000000182 1,3,5-triazines Chemical class 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- PWTFRUXTAFBWBW-UHFFFAOYSA-N 1,3-dibromo-5-(bromomethyl)benzene Chemical compound BrCC1=CC(Br)=CC(Br)=C1 PWTFRUXTAFBWBW-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- RBZMSGOBSOCYHR-UHFFFAOYSA-N 1,4-bis(bromomethyl)benzene Chemical compound BrCC1=CC=C(CBr)C=C1 RBZMSGOBSOCYHR-UHFFFAOYSA-N 0.000 description 1
- PLAOELTXCWXNLY-UHFFFAOYSA-N 1-[4-bromo-2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]azetidin-1-yl]sulfonylphenyl]-N-methylmethanamine Chemical compound BrC1=CC(=C(C=C1)CNC)S(=O)(=O)N1CC(C1)CO[Si](C)(C)C(C)(C)C PLAOELTXCWXNLY-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical class C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- SEQICEWHVVSOCY-ONEGZZNKSA-N 2-[(e)-4-bromobut-2-enyl]isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(C/C=C/CBr)C(=O)C2=C1 SEQICEWHVVSOCY-ONEGZZNKSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- AVCVYLYRVPZDBN-UHFFFAOYSA-N 2-amino-8-bromo-n,n-dipropyl-3h-1-benzazepine-4-carboxamide Chemical compound N1=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C(Br)C=C21 AVCVYLYRVPZDBN-UHFFFAOYSA-N 0.000 description 1
- UVCYDPCWIUABBF-UHFFFAOYSA-N 2-amino-N,N-dipropyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-1-benzazepine-4-carboxamide Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2)B1OC(C(O1)(C)C)(C)C)C(=O)N(CCC)CCC UVCYDPCWIUABBF-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical group NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 1
- WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- LKHAJUQMQNCMOH-UHFFFAOYSA-N 3,3,3-trifluoro-n-propylpropan-1-amine Chemical compound CCCNCCC(F)(F)F LKHAJUQMQNCMOH-UHFFFAOYSA-N 0.000 description 1
- NGZVNONVXYLYQW-UHFFFAOYSA-N 3,3,3-trifluoropropan-1-amine Chemical compound NCCC(F)(F)F NGZVNONVXYLYQW-UHFFFAOYSA-N 0.000 description 1
- BUTKIHRNYUEGKB-UHFFFAOYSA-N 3,3-dimethylbutanoyl chloride Chemical compound CC(C)(C)CC(Cl)=O BUTKIHRNYUEGKB-UHFFFAOYSA-N 0.000 description 1
- KRPRVQWGKLEFKN-UHFFFAOYSA-N 3-(3-aminopropoxy)propan-1-amine Chemical compound NCCCOCCCN KRPRVQWGKLEFKN-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- MUXSUWIHHFNKPP-UHFFFAOYSA-N 4-bromo-2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]azetidin-1-yl]sulfonylbenzaldehyde Chemical compound BrC1=CC(=C(C=O)C=C1)S(=O)(=O)N1CC(C1)CO[Si](C)(C)C(C)(C)C MUXSUWIHHFNKPP-UHFFFAOYSA-N 0.000 description 1
- HGXWRDPQFZKOLZ-UHFFFAOYSA-N 4-bromo-2-fluorobenzonitrile Chemical compound FC1=CC(Br)=CC=C1C#N HGXWRDPQFZKOLZ-UHFFFAOYSA-N 0.000 description 1
- WPVVWLXGHXMNMA-UHFFFAOYSA-N 4-nitro-n-propylbenzenesulfonamide Chemical compound CCCNS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 WPVVWLXGHXMNMA-UHFFFAOYSA-N 0.000 description 1
- BUADMQNRHSFQBR-UHFFFAOYSA-N 5-bromo-2-(bromomethyl)-1-iodo-3-nitrobenzene Chemical compound [O-][N+](=O)c1cc(Br)cc(I)c1CBr BUADMQNRHSFQBR-UHFFFAOYSA-N 0.000 description 1
- VMAQYKGITHDWKL-UHFFFAOYSA-N 5-methylimidazolidine-2,4-dione Chemical compound CC1NC(=O)NC1=O VMAQYKGITHDWKL-UHFFFAOYSA-N 0.000 description 1
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 1
- HOOYOCIMEDJGIC-UHFFFAOYSA-N 8-bromo-3H-1-benzazepin-2-amine Chemical compound NC=1CC=CC2=C(N=1)C=C(C=C2)Br HOOYOCIMEDJGIC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000005748 Aggressive Fibromatosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 208000009945 Angiomatoid fibrous histiocytoma Diseases 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000035821 Benign schwannoma Diseases 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VTTCHVMORRVLEG-UHFFFAOYSA-N BrC=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CNC Chemical compound BrC=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CNC VTTCHVMORRVLEG-UHFFFAOYSA-N 0.000 description 1
- VMAGGXWXRCHFFJ-UHFFFAOYSA-N BrCC1=CC=C(C=C1)CN(S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-])CCC Chemical compound BrCC1=CC=C(C=C1)CN(S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-])CCC VMAGGXWXRCHFFJ-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- AWYDZSPZSIRYRI-UHFFFAOYSA-N C(#N)C=1C=C(C=CC=1)NC(=S)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)OC(C)(C)C Chemical compound C(#N)C=1C=C(C=CC=1)NC(=S)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)OC(C)(C)C AWYDZSPZSIRYRI-UHFFFAOYSA-N 0.000 description 1
- DFVBNOBWHPPVMZ-MDZDMXLPSA-N C(C)(C)(C)OC(=O)N(C(OC(C)(C)C)=O)C\C=C\CN(CCC)S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-] Chemical compound C(C)(C)(C)OC(=O)N(C(OC(C)(C)C)=O)C\C=C\CN(CCC)S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-] DFVBNOBWHPPVMZ-MDZDMXLPSA-N 0.000 description 1
- BHWIRNSVZVUJJH-MDZDMXLPSA-N C(C)(C)(C)OC(=O)N(C(OC(C)(C)C)=O)C\C=C\CN1C(C2=CC=CC=C2C1=O)=O Chemical compound C(C)(C)(C)OC(=O)N(C(OC(C)(C)C)=O)C\C=C\CN1C(C2=CC=CC=C2C1=O)=O BHWIRNSVZVUJJH-MDZDMXLPSA-N 0.000 description 1
- PCLBKLGOEOSEQG-MDZDMXLPSA-N C(C)(C)(C)OC(=O)N(C(OC(C)(C)C)=O)C\C=C\CNCCC Chemical compound C(C)(C)(C)OC(=O)N(C(OC(C)(C)C)=O)C\C=C\CNCCC PCLBKLGOEOSEQG-MDZDMXLPSA-N 0.000 description 1
- HAFZXFBOFXUAHW-BQYQJAHWSA-N C(C)(C)(C)OC(=O)N(C(OC(C)(C)C)=O)C\C=C\CNS(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-] Chemical compound C(C)(C)(C)OC(=O)N(C(OC(C)(C)C)=O)C\C=C\CNS(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-] HAFZXFBOFXUAHW-BQYQJAHWSA-N 0.000 description 1
- GPHYKLPIKWRLAO-UHFFFAOYSA-N C(C)(C)(C)OC(NCCCN(CCC)C(=O)C=1CC(=NC2=C(C=1)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CN(C)C)N)=O Chemical compound C(C)(C)(C)OC(NCCCN(CCC)C(=O)C=1CC(=NC2=C(C=1)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CN(C)C)N)=O GPHYKLPIKWRLAO-UHFFFAOYSA-N 0.000 description 1
- DBZLXKVREHWAEA-UHFFFAOYSA-N C(C1=CC=CC=C1)N(CCCNC1=NC=CC=N1)CCC Chemical compound C(C1=CC=CC=C1)N(CCCNC1=NC=CC=N1)CCC DBZLXKVREHWAEA-UHFFFAOYSA-N 0.000 description 1
- YKVPFMOZSOPEJC-UHFFFAOYSA-N C(C1=CC=CC=C1)N(CCCOCCCNC)CCC Chemical compound C(C1=CC=CC=C1)N(CCCOCCCNC)CCC YKVPFMOZSOPEJC-UHFFFAOYSA-N 0.000 description 1
- ODFIDNFWYGOBOG-UHFFFAOYSA-N C(C1=CC=CC=C1)NCCCOCCCNC(OC(C)(C)C)=O Chemical compound C(C1=CC=CC=C1)NCCCOCCCNC(OC(C)(C)C)=O ODFIDNFWYGOBOG-UHFFFAOYSA-N 0.000 description 1
- YRSVXVAQZFQSMS-UHFFFAOYSA-N C(C1=CC=CC=C1)SC=1C=C(CN(C(OC(C)(C)C)=O)C)C=C(C=1)Br Chemical compound C(C1=CC=CC=C1)SC=1C=C(CN(C(OC(C)(C)C)=O)C)C=C(C=1)Br YRSVXVAQZFQSMS-UHFFFAOYSA-N 0.000 description 1
- RXWUSWIRMXUNOV-UHFFFAOYSA-N C(CC)NCC#CCNC(OC(C)(C)C)=O Chemical compound C(CC)NCC#CCNC(OC(C)(C)C)=O RXWUSWIRMXUNOV-UHFFFAOYSA-N 0.000 description 1
- DICOAYYADHYPCW-UHFFFAOYSA-N C(CC)NCC1=CC=C(C=C1)CN1CCN(CC1)C(=O)OC(C)(C)C Chemical compound C(CC)NCC1=CC=C(C=C1)CN1CCN(CC1)C(=O)OC(C)(C)C DICOAYYADHYPCW-UHFFFAOYSA-N 0.000 description 1
- NXWCPQJZEXHGSP-UHFFFAOYSA-N C(CC)NCCCNC1=NC=CC=N1 Chemical compound C(CC)NCCCNC1=NC=CC=N1 NXWCPQJZEXHGSP-UHFFFAOYSA-N 0.000 description 1
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 1
- 201000004085 CLL/SLL Diseases 0.000 description 1
- XIQRQUJTAHAZCT-UHFFFAOYSA-N COC1=CC=C(C=C1)CCN(C(OC(C)(C)C)=O)CCC Chemical compound COC1=CC=C(C=C1)CCN(C(OC(C)(C)C)=O)CCC XIQRQUJTAHAZCT-UHFFFAOYSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108060002063 Cyclotide Proteins 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- 229930182819 D-leucine Natural products 0.000 description 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000027666 Endometrial Stromal Tumors Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000007207 Epithelioid hemangioendothelioma Diseases 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010015848 Extraskeletal osteosarcomas Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101001011442 Homo sapiens Interferon regulatory factor 5 Proteins 0.000 description 1
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000043138 IRF family Human genes 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100030131 Interferon regulatory factor 5 Human genes 0.000 description 1
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- RPCAZXDMNFBHKB-UHFFFAOYSA-N N'-benzyl-N'-propylpropane-1,3-diamine Chemical compound NCCCN(CCC)CC1=CC=CC=C1 RPCAZXDMNFBHKB-UHFFFAOYSA-N 0.000 description 1
- HIGCCLMKXUSDMX-UHFFFAOYSA-N N,N-dimethyl-1-[1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]sulfonylazetidin-3-yl]methanamine Chemical compound CN(CC1CN(C1)S(=O)(=O)C1=CC(=CC=C1)B1OC(C(O1)(C)C)(C)C)C HIGCCLMKXUSDMX-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical group CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 108010049175 N-substituted Glycines Proteins 0.000 description 1
- ZSUWCLOWOARYAM-UHFFFAOYSA-N N1=CC=C(CC2=C1C=C(C=C2)C(=O)N)C(=O)N Chemical compound N1=CC=C(CC2=C1C=C(C=C2)C(=O)N)C(=O)N ZSUWCLOWOARYAM-UHFFFAOYSA-N 0.000 description 1
- LPBFIUFGDCBSRU-BQYQJAHWSA-N NC/C=C/CN(C(OC(C)(C)C)=O)C(=O)OC(C)(C)C Chemical compound NC/C=C/CN(C(OC(C)(C)C)=O)C(=O)OC(C)(C)C LPBFIUFGDCBSRU-BQYQJAHWSA-N 0.000 description 1
- ZXGLVEWMAOCWHX-MDZDMXLPSA-N NC1=NC2=C(C=C(C1)C(=O)N(C/C=C/CN(C(OC(C)(C)C)=O)C(=O)OC(C)(C)C)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(C/C=C/CN(C(OC(C)(C)C)=O)C(=O)OC(C)(C)C)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO ZXGLVEWMAOCWHX-MDZDMXLPSA-N 0.000 description 1
- MLMLCUNSBGFJRN-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CC#CCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)Br Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CC#CCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)Br MLMLCUNSBGFJRN-UHFFFAOYSA-N 0.000 description 1
- LEFZNMSONBHJMX-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CC#CCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CN(C)C Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CC#CCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CN(C)C LEFZNMSONBHJMX-UHFFFAOYSA-N 0.000 description 1
- BXPUHURECGVMIB-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CC#CCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CC#CCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO BXPUHURECGVMIB-UHFFFAOYSA-N 0.000 description 1
- VXPBVYXXJXMTMB-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC(F)(F)F)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC(F)(F)F)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO VXPBVYXXJXMTMB-UHFFFAOYSA-N 0.000 description 1
- MFZITNQQKLXKHN-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CC1=CC=C(C=C1)CN1CCN(CC1)C(=O)OC(C)(C)C)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CC1=CC=C(C=C1)CN1CCN(CC1)C(=O)OC(C)(C)C)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO MFZITNQQKLXKHN-UHFFFAOYSA-N 0.000 description 1
- XPOIFFGCAKHVCB-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CC1=CC=C(C=C1)CN1CCNCC1)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CC1=CC=C(C=C1)CN1CCNCC1)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO XPOIFFGCAKHVCB-UHFFFAOYSA-N 0.000 description 1
- JJQADULKBWBPEI-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCC1=CC=C(C=C1)OC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCC1=CC=C(C=C1)OC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO JJQADULKBWBPEI-UHFFFAOYSA-N 0.000 description 1
- SDVBUXIIWWZDGG-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCCN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCCN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO SDVBUXIIWWZDGG-UHFFFAOYSA-N 0.000 description 1
- KPEIMWNTHNJURN-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CN(C)C Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CN(C)C KPEIMWNTHNJURN-UHFFFAOYSA-N 0.000 description 1
- OGKIZWOMRNZEJG-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCNC(NC1=CC(=CC=C1)C#N)=O)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCNC(NC1=CC(=CC=C1)C#N)=O)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO OGKIZWOMRNZEJG-UHFFFAOYSA-N 0.000 description 1
- OFSCXGCMWBLWIC-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCNC(NC1=CC(=CC=C1)C#N)=S)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CN(C)C Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCNC(NC1=CC(=CC=C1)C#N)=S)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CN(C)C OFSCXGCMWBLWIC-UHFFFAOYSA-N 0.000 description 1
- PGANLEWDKSCYOI-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCNC(NC1=CC(=CC=C1)C#N)=S)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)CCCNC(NC1=CC(=CC=C1)C#N)=S)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO PGANLEWDKSCYOI-UHFFFAOYSA-N 0.000 description 1
- UDEHPYJSSUYSEK-ONEGZZNKSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)C\C=C\CN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)C\C=C\CN)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO UDEHPYJSSUYSEK-ONEGZZNKSA-N 0.000 description 1
- FNHTZGDVJKPTCV-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCC)OCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCC)OCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO FNHTZGDVJKPTCV-UHFFFAOYSA-N 0.000 description 1
- GSBKADMXVQCMPX-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCCCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCCCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO GSBKADMXVQCMPX-UHFFFAOYSA-N 0.000 description 1
- DWMHUTRPJWZOHC-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO DWMHUTRPJWZOHC-UHFFFAOYSA-N 0.000 description 1
- UICGCCWYBLVRRN-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C(NC1=CC=CC=C1)=O Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C(NC1=CC=CC=C1)=O UICGCCWYBLVRRN-UHFFFAOYSA-N 0.000 description 1
- AGTAMUSEEHZEPM-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CN Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CN AGTAMUSEEHZEPM-UHFFFAOYSA-N 0.000 description 1
- YPYYMNUNEJWIAF-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CNC Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CNC YPYYMNUNEJWIAF-UHFFFAOYSA-N 0.000 description 1
- MAUJBWNALUZOPY-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)N(CCCNC1=NC=CC=N1)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCCNC1=NC=CC=N1)CCC)C=CC(=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO MAUJBWNALUZOPY-UHFFFAOYSA-N 0.000 description 1
- RNESHMNCVAKZOW-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)O)C=CC(=C2)C(NC1=CC=CC=C1)=O Chemical compound NC1=NC2=C(C=C(C1)C(=O)O)C=CC(=C2)C(NC1=CC=CC=C1)=O RNESHMNCVAKZOW-UHFFFAOYSA-N 0.000 description 1
- AQVBXWRDMGWWQV-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)OCC)C=CC(=C2)C(=O)O Chemical compound NC1=NC2=C(C=C(C1)C(=O)OCC)C=CC(=C2)C(=O)O AQVBXWRDMGWWQV-UHFFFAOYSA-N 0.000 description 1
- ZLGWVNGSUXLIGF-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)OCC)C=CC(=C2)C(NC1=CC=CC=C1)=O Chemical compound NC1=NC2=C(C=C(C1)C(=O)OCC)C=CC(=C2)C(NC1=CC=CC=C1)=O ZLGWVNGSUXLIGF-UHFFFAOYSA-N 0.000 description 1
- TZVQASHHLRUXND-UHFFFAOYSA-N NC1=NC2=C(C=C(C1)C(=O)OCC)C=CC(=C2)C=O Chemical compound NC1=NC2=C(C=C(C1)C(=O)OCC)C=CC(=C2)C=O TZVQASHHLRUXND-UHFFFAOYSA-N 0.000 description 1
- NVAZNGNRKHFHAT-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(=O)N(CCC)CCCNC(C1=CC=C(C=C1)OCC)=O Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(=O)N(CCC)CCCNC(C1=CC=C(C=C1)OCC)=O NVAZNGNRKHFHAT-UHFFFAOYSA-N 0.000 description 1
- XKKNIDYKCLVJCN-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(=O)N(CCC)CCCOCCCN Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(=O)N(CCC)CCCOCCCN XKKNIDYKCLVJCN-UHFFFAOYSA-N 0.000 description 1
- FFKDYUFHRLPAQA-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(=O)N(CCC)CCCOCCOCCN Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(=O)N(CCC)CCCOCCOCCN FFKDYUFHRLPAQA-UHFFFAOYSA-N 0.000 description 1
- KKFOOIYMCVUIEU-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(=O)N(CCC)CCNC(OC(C)(C)C)=O Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(=O)N(CCC)CCNC(OC(C)(C)C)=O KKFOOIYMCVUIEU-UHFFFAOYSA-N 0.000 description 1
- IVVLXQKVPLKWLY-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2)C=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CNC(OC(C)(C)C)=O)C(N(CCC)CCC)=O Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2)C=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CNC(OC(C)(C)C)=O)C(N(CCC)CCC)=O IVVLXQKVPLKWLY-UHFFFAOYSA-N 0.000 description 1
- XHOVHQQMQZMEEV-HPJJWIKHSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2)C=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CNC(OCC1=CC=C(C=C1)NC([C@H](CCCNC(=O)N)NC([C@H](C(C)C)N)=O)=O)=O)C(N(CCC)CCC)=O Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2)C=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CNC(OCC1=CC=C(C=C1)NC([C@H](CCCNC(=O)N)NC([C@H](C(C)C)N)=O)=O)=O)C(N(CCC)CCC)=O XHOVHQQMQZMEEV-HPJJWIKHSA-N 0.000 description 1
- AAXZVPRCDUKVFM-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2C#CCCNC(OC(C)(C)C)=O)Br)C(N(CCC)CCC)=O Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2C#CCCNC(OC(C)(C)C)=O)Br)C(N(CCC)CCC)=O AAXZVPRCDUKVFM-UHFFFAOYSA-N 0.000 description 1
- HQFNCNUQKRWQDP-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2C#CCCNC(OC(C)(C)C)=O)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(N(CCC)CCC)=O Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2C#CCCNC(OC(C)(C)C)=O)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(N(CCC)CCC)=O HQFNCNUQKRWQDP-UHFFFAOYSA-N 0.000 description 1
- HPNOCSAODILKTD-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2CCCCN)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(=O)N(CCC)CCC Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2CCCCN)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(=O)N(CCC)CCC HPNOCSAODILKTD-UHFFFAOYSA-N 0.000 description 1
- VLOIEBFQDYRGSS-KDRPCQQKSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2CCCCNC(OCC1=CC=C(C=C1)NC([C@H](CCCNC(=O)N)NC([C@H](C(C)C)N)=O)=O)=O)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(N(CCC)CCC)=O Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2CCCCNC(OCC1=CC=C(C=C1)NC([C@H](CCCNC(=O)N)NC([C@H](C(C)C)N)=O)=O)=O)C1=CC(=CC=C1)S(=O)(=O)N1CC(C1)CO)C(N(CCC)CCC)=O VLOIEBFQDYRGSS-KDRPCQQKSA-N 0.000 description 1
- BLPIMKHZMLODKV-UHFFFAOYSA-N NC=1CC(=CC2=C(N=1)C=C(C=C2I)Br)C(=O)O Chemical compound NC=1CC(=CC2=C(N=1)C=C(C=C2I)Br)C(=O)O BLPIMKHZMLODKV-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- PMEDMSGBAWVRIW-UHFFFAOYSA-N OCCCOCCOCCNC(OC(C)(C)C)=O Chemical compound OCCCOCCOCCNC(OC(C)(C)C)=O PMEDMSGBAWVRIW-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 201000010395 Pleomorphic liposarcoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000037323 Rare tumor Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010066471 Squamous cell carcinoma of pharynx Diseases 0.000 description 1
- 229930183415 Suberin Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- MCMNRKCIXSYSNV-UHFFFAOYSA-N ZrO2 Inorganic materials O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 1
- GZCJVVXAPAWNIY-UHFFFAOYSA-N [2-amino-4-(dipropylcarbamoyl)-3H-1-benzazepin-8-yl]boronic acid Chemical compound NC1=NC2=C(C=C(C1)C(N(CCC)CCC)=O)C=CC(=C2)B(O)O GZCJVVXAPAWNIY-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- DGMMLYHETIWHFI-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(C=C1)S(=O)(=O)N(CCC)CC1=CC=C(C=C1)CN1CCN(CC1)C(=O)OC(C)(C)C Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)S(=O)(=O)N(CCC)CC1=CC=C(C=C1)CN1CCN(CC1)C(=O)OC(C)(C)C DGMMLYHETIWHFI-UHFFFAOYSA-N 0.000 description 1
- QXKJCTXRWSYPRW-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(C=C1)S(=O)(=O)N(CCCCNC(OC(C)(C)C)=O)CCC Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)S(=O)(=O)N(CCCCNC(OC(C)(C)C)=O)CCC QXKJCTXRWSYPRW-UHFFFAOYSA-N 0.000 description 1
- CXQFXTHHFKWRPR-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(C=C1)S(=O)(=O)NCCCCNC(OC(C)(C)C)=O Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)S(=O)(=O)NCCCCNC(OC(C)(C)C)=O CXQFXTHHFKWRPR-UHFFFAOYSA-N 0.000 description 1
- OJAIGZAUURBBQH-UHFFFAOYSA-N [N+](=O)([O-])C=1C=CC(=NC=1)N1CCC(CC1)C(=O)NCCNC(OC(C)(C)C)=O Chemical compound [N+](=O)([O-])C=1C=CC(=NC=1)N1CCC(CC1)C(=O)NCCNC(OC(C)(C)C)=O OJAIGZAUURBBQH-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 150000008038 benzoazepines Chemical class 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000005841 biaryl group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical class N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 201000000292 clear cell sarcoma Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
- 239000004913 cyclooctene Substances 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003236 esophagogastric junction Anatomy 0.000 description 1
- GBRSPJSJVMGTLY-UHFFFAOYSA-N ethyl 2-amino-8-bromo-3h-1-benzazepine-4-carboxylate Chemical compound N1=C(N)CC(C(=O)OCC)=CC2=CC=C(Br)C=C21 GBRSPJSJVMGTLY-UHFFFAOYSA-N 0.000 description 1
- PGDZVUVBEZYPFG-UHFFFAOYSA-N ethyl 3-cyano-2-(triphenyl-$l^{5}-phosphanylidene)propanoate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=C(CC#N)C(=O)OCC)C1=CC=CC=C1 PGDZVUVBEZYPFG-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000008815 extraosseous osteosarcoma Diseases 0.000 description 1
- 206010049444 fibromatosis Diseases 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002518 isoindoles Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 208000010033 lipoblastoma Diseases 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- BKNCSPZEGXUNTP-UHFFFAOYSA-N methyl (4-nitrophenyl) carbonate Chemical compound COC(=O)OC1=CC=C([N+]([O-])=O)C=C1 BKNCSPZEGXUNTP-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- SINWBPLKVKXGPB-UHFFFAOYSA-N n-[2-(4-methoxyphenyl)ethyl]propan-1-amine Chemical compound CCCNCCC1=CC=C(OC)C=C1 SINWBPLKVKXGPB-UHFFFAOYSA-N 0.000 description 1
- OUMBFMLKPJUWDQ-UHFFFAOYSA-N n-benzylpropan-1-amine Chemical compound CCCNCC1=CC=CC=C1 OUMBFMLKPJUWDQ-UHFFFAOYSA-N 0.000 description 1
- UULXSTDDDXOTIY-UHFFFAOYSA-N n-iodoacetamide Chemical compound CC(=O)NI UULXSTDDDXOTIY-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000011858 nanopowder Substances 0.000 description 1
- 239000002073 nanorod Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 208000025275 nodular sclerosis classical Hodgkin lymphoma Diseases 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical compound C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- AQFWNELGMODZGC-UHFFFAOYSA-N o-ethylhydroxylamine Chemical compound CCON AQFWNELGMODZGC-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 208000010655 oral cavity squamous cell carcinoma Diseases 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000009612 pediatric lymphoma Diseases 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- RDBMUARQWLPMNW-UHFFFAOYSA-N phosphanylmethanol Chemical compound OCP RDBMUARQWLPMNW-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 201000002217 pleomorphic lipoma Diseases 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003135 prenol lipids Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001350 reed-sternberg cell Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002107 sheath cell Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 208000014653 solitary fibrous tumor Diseases 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 201000002245 spindle cell lipoma Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- XIVHGTLMLORWEP-UHFFFAOYSA-N tert-butyl 3-[2-(2-aminoethoxy)ethoxy]propanoate Chemical compound CC(C)(C)OC(=O)CCOCCOCCN XIVHGTLMLORWEP-UHFFFAOYSA-N 0.000 description 1
- NFFYYOMCGKBHBE-UHFFFAOYSA-N tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-oxoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate Chemical compound CC(C)(C)OC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCC=O NFFYYOMCGKBHBE-UHFFFAOYSA-N 0.000 description 1
- QOVWBOVPARDQMA-UHFFFAOYSA-N tert-butyl N-[2-[2-[3-(propylamino)propoxy]ethoxy]ethyl]carbamate Chemical compound C(CC)NCCCOCCOCCNC(OC(C)(C)C)=O QOVWBOVPARDQMA-UHFFFAOYSA-N 0.000 description 1
- CPNNUYCWNQIWIT-UHFFFAOYSA-N tert-butyl N-[2-[2-[3-[benzyl(propyl)amino]propoxy]ethoxy]ethyl]carbamate Chemical compound C(C1=CC=CC=C1)N(CCCOCCOCCNC(OC(C)(C)C)=O)CCC CPNNUYCWNQIWIT-UHFFFAOYSA-N 0.000 description 1
- DORMLIQQCOGECW-UHFFFAOYSA-N tert-butyl N-[3-[3-(propylamino)propoxy]propyl]carbamate Chemical compound C(CC)NCCCOCCCNC(OC(C)(C)C)=O DORMLIQQCOGECW-UHFFFAOYSA-N 0.000 description 1
- JKMPDKDIYMXMKO-UHFFFAOYSA-N tert-butyl N-[3-[[2-amino-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-1-benzazepine-4-carbonyl]-propylamino]propyl]carbamate Chemical compound NC1=NC2=C(C=C(C1)C(=O)N(CCCNC(OC(C)(C)C)=O)CCC)C=CC(=C2)B1OC(C(O1)(C)C)(C)C JKMPDKDIYMXMKO-UHFFFAOYSA-N 0.000 description 1
- LQBNSKOZUIPVMG-UHFFFAOYSA-N tert-butyl N-[[1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]sulfonylazetidin-3-yl]methyl]carbamate Chemical compound CC1(OB(OC1(C)C)C=1C=C(C=CC=1)S(=O)(=O)N1CC(C1)CNC(OC(C)(C)C)=O)C LQBNSKOZUIPVMG-UHFFFAOYSA-N 0.000 description 1
- JGCLXXLCXXTYCA-UHFFFAOYSA-N tert-butyl N-[[4-[2-amino-4-(dipropylcarbamoyl)-3H-1-benzazepin-8-yl]-2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]azetidin-1-yl]sulfonylphenyl]methyl]-N-methylcarbamate Chemical compound NC1=NC2=C(C=C(C1)C(N(CCC)CCC)=O)C=CC(=C2)C1=CC(=C(C=C1)CN(C(OC(C)(C)C)=O)C)S(=O)(=O)N1CC(C1)CO[Si](C)(C)C(C)(C)C JGCLXXLCXXTYCA-UHFFFAOYSA-N 0.000 description 1
- OQHODGVUOOGEJA-UHFFFAOYSA-N tert-butyl N-ethoxy-N-propylcarbamate Chemical compound C(C)(C)(C)OC(N(CCC)OCC)=O OQHODGVUOOGEJA-UHFFFAOYSA-N 0.000 description 1
- XWQAAAUEEPAJQH-UHFFFAOYSA-N tert-butyl N-methyl-N-[3-(propylamino)propyl]carbamate Chemical compound CCCNCCCN(C)C(=O)OC(C)(C)C XWQAAAUEEPAJQH-UHFFFAOYSA-N 0.000 description 1
- KDMHTXJIBDWYMK-UHFFFAOYSA-N tert-butyl N-propyl-N-(3,3,3-trifluoropropyl)carbamate Chemical compound CCCN(CCC(F)(F)F)C(=O)OC(C)(C)C KDMHTXJIBDWYMK-UHFFFAOYSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- GCJVFCJZMWUURS-UHFFFAOYSA-N tert-butyl n-(3,3,3-trifluoropropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCC(F)(F)F GCJVFCJZMWUURS-UHFFFAOYSA-N 0.000 description 1
- PNQYAMWGTGWJDW-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)-n-methylcarbamate Chemical compound NCCCN(C)C(=O)OC(C)(C)C PNQYAMWGTGWJDW-UHFFFAOYSA-N 0.000 description 1
- POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
- ZFQWJXFJJZUVPI-UHFFFAOYSA-N tert-butyl n-(4-aminobutyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCN ZFQWJXFJJZUVPI-UHFFFAOYSA-N 0.000 description 1
- DPLOGSUBQDREOU-UHFFFAOYSA-N tert-butyl n-(5-aminopentyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCN DPLOGSUBQDREOU-UHFFFAOYSA-N 0.000 description 1
- HRJJBEIFHFVBRT-UHFFFAOYSA-N tert-butyl n-[(4-formylphenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C=O)C=C1 HRJJBEIFHFVBRT-UHFFFAOYSA-N 0.000 description 1
- WEPYXLCLPJGRDP-UHFFFAOYSA-N tert-butyl n-[2-(4-methoxyphenyl)ethyl]carbamate Chemical compound COC1=CC=C(CCNC(=O)OC(C)(C)C)C=C1 WEPYXLCLPJGRDP-UHFFFAOYSA-N 0.000 description 1
- OQQUULQVOXUSIB-UHFFFAOYSA-N tert-butyl n-[4-(propylamino)butyl]carbamate Chemical compound CCCNCCCCNC(=O)OC(C)(C)C OQQUULQVOXUSIB-UHFFFAOYSA-N 0.000 description 1
- BWNQTGRBVMERHU-UHFFFAOYSA-N tert-butyl n-but-3-ynylcarbamate Chemical compound CC(C)(C)OC(=O)NCCC#C BWNQTGRBVMERHU-UHFFFAOYSA-N 0.000 description 1
- HZDXVYCENFYZSA-UHFFFAOYSA-N tert-butyl n-ethoxycarbamate Chemical compound CCONC(=O)OC(C)(C)C HZDXVYCENFYZSA-UHFFFAOYSA-N 0.000 description 1
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本特許出願は、2019年6月13日付で出願された米国仮特許出願62/861,117号、2019年6月13日付で出願された米国仮特許出願62/861,139号、および2020年1月21日付で出願された米国仮特許出願62/963,884号の優先権を主張し、それらのそれぞれは、参照によりその全体が本明細書に組み込まれる。
本発明は、一般に、1つ以上のアミノベンズアゼピン分子に接合された高分子支持体を含む高分子支持化合物に関する。
診断アッセイ、薬物動態検出、抗体生成、および疾患(例えば、癌)の治療のために、新しい接合体および組成物が必要とされている。接合体および組成物は、アクセスできない腫瘍に到達するための免疫アジュバントの送達および/または癌患者および他の対象についての治療選択肢を拡大するための他の免疫接合体の開発のための方法において直接使用することができる。本発明は、そのような免疫アジュバント、接合体、組成物、および方法を提供する。
ここで、本発明の特定の実施態様を詳細に参照し、その例を添付の構造および式中に例示する。本発明は、列挙した実施態様と組み合わせて説明するが、列挙した実施態様は、本発明をそれらの実施態様に限定することを意図するものではないことが理解されるであろう。それどころか、本発明は、特許請求の範囲によって定義される本発明の範囲内に含まれ得る全ての代替物、修飾体、および同等物をカバーすることを意図している。
本明細書において使用される句「高分子支持化合物」は、連結部分を介してTLRアゴニストに共有結合している高分子支持体を指す。
アミノベンズアゼピンアジュバント化合物
本発明の高分子支持化合物は、高分子支持体のアミノベンズアゼピン-リンカー化合物との接合によって製造する。アミノベンズアゼピン-リンカー化合物は、リンカーユニットに共有結合したアミノベンズアゼピン部分を含む。リンカーユニットは、高分子支持化合物の安定性、透過性、溶解性、および他の薬物動態、安全性、並びに有効性の特性に影響を与える官能基およびサブユニットを含む。当業者は、高分子支持化合物中のアミノベンズアゼピン-リンカー化合物がさまざまな化学を使用して高分子支持体に共有結合し得、本明細書において記載される官能基連結部分が高分子支持体(例えば、アミノ酸側鎖、表面アルコール、チオール、カルボニル、酸、またはアミン、核酸等)の任意の遊離官能基と反応し得ることを認識するであろう。例えば、高分子支持体のリジン側鎖アミノなどの求核基は、アミノベンズアゼピン-リンカー化合物の求電子反応性官能基と反応して、高分子支持化合物を形成する。また、例えば、高分子支持体のシステインチオールは、アミノベンズアゼピン-リンカー化合物のマレイミドまたはブロモアセトアミド基と反応して、高分子支持化合物を形成する。
Zは、H、-O(C1-C8アルキル)、およびN(X2R2)(X3R3)から選択され;
R1、R2、R3、およびR4は、H、C1-C12アルキル、C2-C6アルケニル、C2-C6アルキニル、C3-C12カルボシクリル、C6-C20アリール、C2-C9ヘテロシクリル、およびC1-C20ヘテロアリールからなる群から独立して選択され、ここで、アルキル、アルケニル、アルキニル、カルボシクリル、アリール、ヘテロシクリル、およびヘテロアリールは、
-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-N(R5)2;
-(C3-C12カルボシクリル);
-(C3-C12カルボシクリル)-*;
-(C3-C12カルボシクリル)-(C1-C12アルキルジイル)-NR5-*;
-(C3-C12カルボシクリル)-(C1-C12アルキルジイル)-N(R5)2;
-(C3-C12カルボシクリル)-NR5-C(=NR5)NR5-*;
-(C6-C20アリール);
-(C6-C20アリール)-*;
-(C6-C20アリールジイル)-N(R5)-*;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)2;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-NR5-C(=NR5a)N(R5)-*;
-(C2-C20ヘテロシクリル);
-(C2-C20ヘテロシクリル)-*;
-(C2-C9ヘテロシクリル)-(C1-C12アルキルジイル)-NR5-*;
-(C2-C9ヘテロシクリル)-(C1-C12アルキルジイル)-N(R5)2;
-(C2-C9ヘテロシクリル)-NR5-C(=NR5a)NR5-*;
-(C1-C20ヘテロアリール);
-(C1-C20ヘテロアリール)-*;
-(C1-C20ヘテロアリール)-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C20ヘテロアリール)-(C1-C12アルキルジイル)-N(R5)2;
-(C1-C20ヘテロアリール)-NR5-C(=NR5a)N(R5)-*;
-C(=O)-*;
-C(=O)-(C2-C20ヘテロシクリルジイル)-*;
-C(=O)N(R5)2;
-C(=O)N(R5)-*;
-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)R5;
-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)N(R5)2;
-C(=O)NR5-(C1-C12アルキルジイル)-N(R5)CO2R5;
-C(=O)NR5-(C1-C12アルキルジイル)-N(R5)C(=NR5a)N(R5)2;
-C(=O)NR5-(C1-C12アルキルジイル)-NR5C(=NR5a)R5;
-C(=O)NR5-(C1-C8アルキルジイル)-NR5(C2-C5ヘテロアリール);
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-N(R5)-*;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-*;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-(C1-C12アルキルジイル)-N(R5)2;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-(C2-C20ヘテロシクリルジイル)-C(=O)NR5-(C1-C12アルキルジイル)-NR5-*;
-N(R5)2;
-N(R5)-*;
-N(R5)C(=O)R5;
-N(R5)C(=O)-*;
-N(R5)C(=O)N(R5)2;
-N(R5)C(=O)N(R5)-*;
-N(R5)CO2R5;
-NR5C(=NR5a)N(R5)2;
-NR5C(=NR5a)N(R5)-*;
-NR5C(=NR5a)R5;
-N(R5)-(C2-C5ヘテロアリール);
-O-(C1-C12アルキル);
-O-(C1-C12アルキルジイル)-N(R5)2;
-O-(C1-C12アルキルジイル)-N(R5)-*;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-*;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-N(R5)2;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-NR5-*;および
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-OH
から選択される1つ以上の基で独立してかつ任意に置換されており;
またはR2およびR3が一緒になって、5若しくは6員のヘテロシクリル環を形成し;
X1、X2、X3、およびX4は、結合、C(=O)、C(=O)N(R5)、O、N(R5)、S、S(O)2、およびS(O)2N(R5)からなる群から独立して選択され;
R5は、H、C6-C20アリール、C6-C20アリールジイル、C1-C12アルキル、およびC1-C12アルキルジイルからなる基から選択されるか、または2つのR5基が一緒になって、5若しくは6員のヘテロシクリル環を形成し;
R5aは、C6-C20アリールおよびC1-C20ヘテロアリールからなる群から選択され;
ここで、アスタリスク*は、Lの接続サイトを示し、R1、R2、R3、およびR4の1つは、Lに接続されており;
Lは、
Q-C(=O)-(PEG)-;
Q-C(=O)-(PEG)-C(=O)-;
Q-C(=O)-(PEG)-O-;
Q-C(=O)-(PEG)-C(=O)-(PEP)-;
Q-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-;
Q-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
Q-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-(MCgluc)-;
Q-C(=O)-(PEG)-C(=O)-(MCgluc)-;
Q-C(=O)-(PEG)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-;
Q-C(=O)-(PEG)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
Q-C(=O)-(PEG)-N(R5)-;
Q-C(=O)-(PEG)-N(R5)-(PEG)-C(=O)-(PEP)-;
Q-C(=O)-(PEG)-N+(R5)2-(PEG)-C(=O)-(PEP)-;
Q-C(=O)-(PEG)-C(=O)-N(R5)CH(AA1)C(=O)-(PEG)-C(=O)-(PEP)-;
Q-C(=O)-(PEG)-C(=O)-N(R5)CH(AA1)C(=O)-N(R5)-(C1-C12アルキルジイル)-;
Q-C(=O)-(PEG)-SS-(C1-C12アルキルジイル)-OC(=O)-;
Q-C(=O)-(PEG)-SS-(C1-C12アルキルジイル)-C(=O)-;
Q-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-;
Q-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-;
Q-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)-C(=O);
Q-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
Q-C(=O)-CH2CH2OCH2CH2-(C1-C20ヘテロアリールジイル)-CH2O-(PEG)-C(=O)-(MCgluc)-;
Q-C(=O)-CH2CH2OCH2CH2-(C1-C20ヘテロアリールジイル)-CH2O-(PEG)-C(=O)-(MCgluc)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;および
Q-(CH2)m-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-
からなる群から選択されるリンカーであり;
ここで、PEGは、式:-(CH2CH2O)n-(CH2)m-を有し;mは、1から5の整数であり、nは、2から50の整数であり;
PEPは、式:
R6は、-CH2O-C(=O)-および任意に
MCglucは、基:
Qは、N-ヒドロキシスクシンイミジル、N-ヒドロキシスルホスクシンイミジル、マレイミド、およびF、Cl、NO2、およびSO3 -から独立して選択される1つ以上の基で置換されたフェノキシからなる群から選択され;
ここで、アルキル、アルキルジイル、アルケニル、アルケニルジイル、アルキニル、アルキニルジイル、アリール、アリールジイル、カルボシクリル、カルボシクリルジイル、ヘテロシクリル、ヘテロシクリルジイル、ヘテロアリール、およびヘテロアリールジイルは、F、Cl、Br、I、-CN、-CH3、-CH2CH3、-CH=CH2、-C≡CH、-C≡CCH3、-CH2CH2CH3、-CH(CH3)2、-CH2CH(CH3)2、-CH2OH、-CH2OCH3、-CH2CH2OH、-C(CH3)2OH、-CH(OH)CH(CH3)2、-C(CH3)2CH2OH、-CH2CH2SO2CH3、-CH2OP(O)(OH)2、-CH2F、-CHF2、-CF3、-CH2CF3、-CH2CHF2、-CH(CH3)CN、-C(CH3)2CN、-CH2CN、-CH2NH2、-CH2NHSO2CH3、-CH2NHCH3、-CH2N(CH3)2、-CO2H、-COCH3、-CO2CH3、-CO2C(CH3)3、-COCH(OH)CH3、-CONH2、-CONHCH3、-CON(CH3)2、-C(CH3)2CONH2、-NH2、-NHCH3、-N(CH3)2、-NHCOCH3、-N(CH3)COCH3、-NHS(O)2CH3、-N(CH3)C(CH3)2CONH2、-N(CH3)CH2CH2S(O)2CH3、-NHC(=NH)H、-NHC(=NH)CH3、-NHC(=NH)NH2、-NHC(=O)NH2、-NO2、=O、-OH、-OCH3、-OCH2CH3、-OCH2CH2OCH3、-OCH2CH2OH、-OCH2CH2N(CH3)2、-O(CH2CH2O)n-(CH2)mCO2H、-O(CH2CH2O)nH、-OP(O)(OH)2、-S(O)2N(CH3)2、-SCH3、-S(O)2CH3、および-S(O)3Hから独立して選択される1つ以上の基で任意に置換されている)のアミノベンズアゼピン-リンカー化合物を含む。
高分子支持化合物の例示的な実施態様は、1つ以上のアミノベンズアゼピン部分に共有結合した二価リンカーに共有結合し、式I:
「MS」は、高分子支持体であり;
pは、1から50の整数であり;
Bzaは、式:
-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-N(R5)2;
-(C3-C12カルボシクリル);
-(C3-C12カルボシクリル)-*;
-(C3-C12カルボシクリル)-(C1-C12アルキルジイル)-NR5-*;
-(C3-C12カルボシクリル)-(C1-C12アルキルジイル)-N(R5)2;
-(C3-C12カルボシクリル)-NR5-C(=NR5)NR5-*;
-(C6-C20アリ-ル);
-(C6-C20アリ-ル)-*;
-(C6-C20アリ-ルジイル)-N(R5)-*;
-(C6-C20アリ-ルジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C6-C20アリ-ルジイル)-(C1-C12アルキルジイル)-N(R5)2;
-(C6-C20アリ-ルジイル)-(C1-C12アルキルジイル)-NR5-C(=NR5a)N(R5)-*;
-(C2-C20ヘテロシクリル);
-(C2-C20ヘテロシクリル)-*;
-(C2-C9ヘテロシクリル)-(C1-C12アルキルジイル)-NR5-*;
-(C2-C9ヘテロシクリル)-(C1-C12アルキルジイル)-N(R5)2;
-(C2-C9ヘテロシクリル)-NR5-C(=NR5a)NR5-*;
-(C1-C20ヘテロアリ-ル);
-(C1-C20ヘテロアリ-ル)-*;
-(C1-C20ヘテロアリ-ル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C20ヘテロアリ-ル)-(C1-C12アルキルジイル)-N(R5)2;
-(C1-C20ヘテロアリ-ル)-NR5-C(=NR5a)N(R5)-*;
-C(=O)-*;
-C(=O)-(C2-C20ヘテロシクリルジイル)-*;
-C(=O)N(R5)2;
-C(=O)N(R5)-*;
-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)R5;
-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)N(R5)2;
-C(=O)NR5-(C1-C12アルキルジイル)-N(R5)CO2R5;
-C(=O)NR5-(C1-C12アルキルジイル)-N(R5)C(=NR5a)N(R5)2;
-C(=O)NR5-(C1-C12アルキルジイル)-NR5C(=NR5a)R5;
-C(=O)NR5-(C1-C8アルキルジイル)-NR5(C2-C5ヘテロアリ-ル);
-C(=O)NR5-(C1-C20ヘテロアリ-ルジイル)-N(R5)-*;
-C(=O)NR5-(C1-C20ヘテロアリ-ルジイル)-*;
-C(=O)NR5-(C1-C20ヘテロアリ-ルジイル)-(C1-C12アルキルジイル)-N(R5)2;
-C(=O)NR5-(C1-C20ヘテロアリ-ルジイル)-(C2-C20ヘテロシクリルジイル)-C(=O)NR5-(C1-C12アルキルジイル)-NR5-*;
-N(R5)2;
-N(R5)-*;
-N(R5)C(=O)R5;
-N(R5)C(=O)-*;
-N(R5)C(=O)N(R5)2;
-N(R5)C(=O)N(R5)-*;
-N(R5)CO2R5;
-NR5C(=NR5a)N(R5)2;
-NR5C(=NR5a)N(R5)-*;
-NR5C(=NR5a)R5;
-N(R5)-(C2-C5ヘテロアリ-ル);
-O-(C1-C12アルキル);
-O-(C1-C12アルキルジイル)-N(R5)2;
-O-(C1-C12アルキルジイル)-N(R5)-*;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-*;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-N(R5)2;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-NR5-*;および
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-OH
から選択される1つ以上の基で独立してかつ任意に置換されており;
またはR2およびR3が一緒になって、5若しくは6員のヘテロシクリル環を形成し;
X1、X2、X3、およびX4は、結合、C(=O)、C(=O)N(R5)、O、N(R5)、S、S(O)2、およびS(O)2N(R5)からなる群から独立して選択され;
R5は、H、C6-C20アリ-ル、C6-C20アリ-ルジイル、C1-C12アルキル、およびC1-C12アルキルジイルからなる基から選択されるか、または2つのR5基が一緒になって、5若しくは6員のヘテロシクリル環を形成し;
R5aは、C6-C20アリ-ルおよびC1-C20ヘテロアリ-ルからなる群から選択され;
ここで、アスタリスク*は、Lの接続サイトを示し、R1、R2、R3、およびR4の1つがLに接続されており;
Lは、
-C(=O)-(PEG)-;
-C(=O)-(PEG)-C(=O)-;
-C(=O)-(PEG)-O-;
-C(=O)-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-(MCgluc)-;
-C(=O)-(PEG)-C(=O)-(MCgluc)-;
-C(=O)-(PEG)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(PEG)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
-C(=O)-(PEG)-N(R5)-;
-C(=O)-(PEG)-N(R5)-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-N+(R5)2-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-C(=O)-N(R5)CH(AA1)C(=O)-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-C(=O)-N(R5)CH(AA1)C(=O)-N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(PEG)-SS-(C1-C12アルキルジイル)-OC(=O)-;
-C(=O)-(PEG)-SS-(C1-C12アルキルジイル)-C(=O)-;
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-;
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)-C(=O);
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
-C(=O)-CH2CH2OCH2CH2-(C1-C20ヘテロアリ-ルジイル)-CH2O-(PEG)-C(=O)-(MCgluc)-;
-C(=O)-CH2CH2OCH2CH2-(C1-C20ヘテロアリ-ルジイル)-CH2O-(PEG)-C(=O)-(MCgluc)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;および
-(スクシンイミジル)-(CH2)m-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-
からなる群から選択されるリンカーであり;
PEGは、式:-(CH2CH2O)n-(CH2)m-を有し;mは、1から5の整数であり、nは、2から50の整数であり;
PEPは、式:
R6は、-CH2O-C(=O)-および任意に
MCglucは、基:
アルキル、アルキルジイル、アルケニル、アルケニルジイル、アルキニル、アルキニルジイル、アリ-ル、アリ-ルジイル、カルボシクリル、カルボシクリルジイル、ヘテロシクリル、ヘテロシクリルジイル、ヘテロアリ-ル、およびヘテロアリ-ルジイルは、F、Cl、Br、I、-CN、-CH3、-CH2CH3、-CH=CH2、-C≡CH、-C≡CCH3、-CH2CH2CH3、-CH(CH3)2、-CH2CH(CH3)2、-CH2OH、-CH2OCH3、-CH2CH2OH、-C(CH3)2OH、-CH(OH)CH(CH3)2、-C(CH3)2CH2OH、-CH2CH2SO2CH3、-CH2OP(O)(OH)2、-CH2F、-CHF2、-CF3、-CH2CF3、-CH2CHF2、-CH(CH3)CN、-C(CH3)2CN、-CH2CN、-CH2NH2、-CH2NHSO2CH3、-CH2NHCH3、-CH2N(CH3)2、-CO2H、-COCH3、-CO2CH3、-CO2C(CH3)3、-COCH(OH)CH3、-CONH2、-CONHCH3、-CON(CH3)2、-C(CH3)2CONH2、-NH2、-NHCH3、-N(CH3)2、-NHCOCH3、-N(CH3)COCH3、-NHS(O)2CH3、-N(CH3)C(CH3)2CONH2、-N(CH3)CH2CH2S(O)2CH3、-NHC(=NH)H、-NHC(=NH)CH3、-NHC(=NH)NH2、-NHC(=O)NH2、-NO2、=O、-OH、-OCH3、-OCH2CH3、-OCH2CH2OCH3、-OCH2CH2OH、-OCH2CH2N(CH3)2、-O(CH2CH2O)n-(CH2)mCO2H、-O(CH2CH2O)nH、-OP(O)(OH)2、-S(O)2N(CH3)2、-SCH3、-S(O)2CH3、および-S(O)3Hから独立して選択される1つ以上の基で独立してかつ任意に置換されている)を有するアミノベンズアゼピン部分である)を有する高分子支持体またはその薬学的に許容される塩を含む。
-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-N(R5)C(=NR5)N(R5)-*;
-(C6-C20アリールジイル)-S(=O)2-(C2-C20ヘテロシクリルジイル)-*;
-(C6-C20アリールジイル)-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C6-C20アリールジイル)-C(=O)-*;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C6-C20アリールジイル)-C(=O)-(C2-C20ヘテロシクリルジイル)-*;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-*;および
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-(C2-C20ヘテロシクリルジイル)-C(=O)NR5-(C1-C12アルキルジイル)-NR5-*
から選択されるものを含む。
-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-O-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-N(R5)C(=NR5)-N(R5)-*;
-(C1-C12アルキルジイル)-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-C(=NR5)N(R5)-*;
-(C2-C6アルキニルジイル)-N(R5)-*;および
-(C2-C6アルキニルジイル)-N(R5)C(=NR5)N(R5)-*
から選択され;
X2およびX3が結合であり、ここで、アスタリスク*がLの接続サイトを示すものを含む。
各Zは独立して、水素であるかまたは式:
Uは、任意に存在して、CH2、C(=O)、CH2C(=O)、またはC(=O)CH2であり、
Aは、任意に存在して、NR10であるかまたは式:
R10およびWは独立して、水素、Ar1、または式:
Vは、任意に存在して、式:
J1およびJ2は独立して、CHまたはNであり、
m1、m2、およびm3は独立して、m1、m2、およびm3の少なくとも1つがゼロでない整数であることを除いて、0から25の整数であり、
n1、n2、n3、n4、n5、およびn6は独立して、0から10の整数であり、
t1およびt2は独立して、1から3の整数であり、
G1、G2、G3、およびG4は独立して、CH2、C(=O)、CH2C(=O)、C(=O)CH2、または結合であり、
X1、X2、X3、およびX4は、それぞれ任意に存在して、独立して、O、NR7、CHR7、SO2、S、あるいは1つ若しくは2つのシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基であり、複数のシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基が存在するとき、該複数のシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基は、連結または縮合しており、ここで、連結したシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基は、結合または-CO-を通して連結しており、
R9は、水素、C1-C4アルキルであるか、または式:
R8は、独立して水素またはC1-C4アルキルであり、
Ar1およびAr2は独立して、1つ以上のハロゲン(例えば、フッ素、塩素、臭素、またはヨウ素)、ニトリル、ヒドロキシル、C1-C4アルキル基、若しくはそれらの組合せで任意に置換された、アリールまたはヘテロアリール基であり、
LMは、アミド、アミン、エステル、カルバメート、尿素、チオエーテル、チオカルバメート、チオカーボネート、およびチオ尿素から選択される官能基を含む連結部分であり、
rは、1から50の整数であり、
「MS」は、高分子支持体であり、
各波線
本発明の高分子支持化合物は、高分子支持体を含む。単一の物質として、高分子支持体は、本明細書において記載されるアミノベンズアゼピン化合物と比較して生物学的に活性でまたは生物学的に不活性であり得る。しかしながら、アミノベンズアゼピン化合物と組み合わせて使用するとき、アミノベンズアゼピン化合物の生物学的活性は、例えば、標的効果を提供することによって、有益なオフターゲット効果(すなわち、TLR活性以外の生物学的活性)、改善された薬物動態特性(例えば、半減期延長)、増強された生物学的送達(例えば、腫瘍浸透)を提供することによって、または追加の生物学的刺激、分化、アップレギュレーション、および/若しくはダウンレギュレーションを提供することによって、増強される。特定の実施形態において、高分子支持体およびアミノベンズアゼピン化合物の生物学的効果は相乗的であり、すなわち、単一の物質としての高分子支持体およびアミノベンズアゼピン化合物のそれぞれの生物学的活性の合計よりも大きい。
本発明は、本明細書において記載される複数の高分子支持化合物および任意にそのための担体、例えば、薬学的に許容される担体を含む、組成物、例えば、薬学的に許容される組成物または製剤を提供する。高分子支持化合物は、組成において同じでありまたは異なり得、すなわち、組成物は、高分子支持化合物の同じ化学物質に連結した同じ数のアミノベンズアゼピン化合物を有する高分子支持化合物、高分子支持化合物の異なる化学物質に連結した同じ数のアミノベンズアゼピン化合物を有する、高分子支持化合物の同じ化学物質に連結した異なる数のアミノベンズアゼピン化合物を有する、および/または高分子支持化合物の異なる化学物質に連結した異なる数のアミノベンズアゼピン化合物を有する高分子支持化合物を含み得る。
本発明は、治療、診断、または化学アッセイにおける使用のためのTLR(例えば、TLR7および/またはTLR8)を認識する方法を提供する。特定の理論に拘束されることを望むことなく、TLRは、本明細書において記載される高分子支持化合物がTLRの存在および/または豊富さを評価することにおいて有用であるように、本明細書において記載されるアジュバント/リンカーの組合せに対して高い親和性を有する。特定の実施態様においては、高分子支持化合物は、TLRの関与および/または活性についての化学アッセイとして使用される。そのような実施態様においては、高分子支持体は、樹脂、ビーズ、プローブ、タグ、ウェル、またはプレートであり得る。特定の実施態様においては、高分子支持化合物は、TLRに関連する疾患の治療用または診断用として使用される。そのような実施態様においては、高分子支持体は、典型的には少なくとも約200Da(例えば、少なくとも約500Da、少なくとも約1,000Da、少なくとも約2,000Da、少なくとも約5,000Da、または少なくとも約10,000Da)の分子量を有する化学構造(例えば、生物学的構造または無機フレームワーク)である。
本明細書において記載される本発明の実施態様を含む一面は、単独でまたは1つ以上の他の一面若しくは実施態様と組み合わせて有益であり得る。前述の説明を制限することなく、1~49と番号付けされた本開示の特定の非限定的な一面を、以下に提供する。本開示を読むと当業者には明らかであろうように、個別に番号付けされた一面のそれぞれは、先行のまたは後続の個別に番号付けされた一面のいずれかと一緒に使用しまたは組み合わせ得る。これは、全てのそのような一面の組合せについてのサポートを提供することを意図しており、以下に明示的に提供される一面の組合せに限定されない。
(式中:
「MS」は、高分子支持体であり;
pは、1から50の整数であり;
Bzaは、式:
-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-N(R5)2;
-(C3-C12カルボシクリル);
-(C3-C12カルボシクリル)-*;
-(C3-C12カルボシクリル)-(C1-C12アルキルジイル)-NR5-*;
-(C3-C12カルボシクリル)-(C1-C12アルキルジイル)-N(R5)2;
-(C3-C12カルボシクリル)-NR5-C(=NR5)NR5-*;
-(C6-C20アリール);
-(C6-C20アリール)-*;
-(C6-C20アリールジイル)-N(R5)-*;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)2;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-NR5-C(=NR5a)N(R5)-*;
-(C2-C20ヘテロシクリル);
-(C2-C20ヘテロシクリル)-*;
-(C2-C9ヘテロシクリル)-(C1-C12アルキルジイル)-NR5-*;
-(C2-C9ヘテロシクリル)-(C1-C12アルキルジイル)-N(R5)2;
-(C2-C9ヘテロシクリル)-NR5-C(=NR5a)NR5-*;
-(C1-C20ヘテロアリール);
-(C1-C20ヘテロアリール)-*;
-(C1-C20ヘテロアリール)-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C20ヘテロアリール)-(C1-C12アルキルジイル)-N(R5)2;
-(C1-C20ヘテロアリール)-NR5-C(=NR5a)N(R5)-*;
-C(=O)-*;
-C(=O)-(C2-C20ヘテロシクリルジイル)-*;
-C(=O)N(R5)2;
-C(=O)N(R5)-*;
-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)R5;
-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)N(R5)2;
-C(=O)NR5-(C1-C12アルキルジイル)-N(R5)CO2R5;
-C(=O)NR5-(C1-C12アルキルジイル)-N(R5)C(=NR5a)N(R5)2;
-C(=O)NR5-(C1-C12アルキルジイル)-NR5C(=NR5a)R5;
-C(=O)NR5-(C1-C8アルキルジイル)-NR5(C2-C5ヘテロアリール);
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-N(R5)-*;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-*;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-(C1-C12アルキルジイル)-N(R5)2;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-(C2-C20ヘテロシクリルジイル)-C(=O)NR5-(C1-C12アルキルジイル)-NR5-*;
-N(R5)2;
-N(R5)-*;
-N(R5)C(=O)R5;
-N(R5)C(=O)-*;
-N(R5)C(=O)N(R5)2;
-N(R5)C(=O)N(R5)-*;
-N(R5)CO2R5;
-NR5C(=NR5a)N(R5)2;
-NR5C(=NR5a)N(R5)-*;
-NR5C(=NR5a)R5;
-N(R5)-(C2-C5ヘテロアリール);
-O-(C1-C12アルキル);
-O-(C1-C12アルキルジイル)-N(R5)2;
-O-(C1-C12アルキルジイル)-N(R5)-*;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-*;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-N(R5)2;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-NR5-*;および
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-OH
から選択される1つ以上の基で独立してかつ任意に置換されており;
またはR2およびR3が一緒になって、5若しくは6員のヘテロシクリル環を形成し;
R5は、H、C6-C20アリール、C6-C20アリールジイル、C1-C12アルキル、およびC1-C12アルキルジイルからなる基から選択されるか、または2つのR5基が一緒になって、5若しくは6員のヘテロシクリル環を形成し;
R5aは、C6-C20アリールおよびC1-C20ヘテロアリールからなる群から選択され;
ここで、アスタリスク*は、Lの接続サイトを示し、R1、R2、R3、およびR4の1つは、Lに接続されており;
-C(=O)-(PEG)-;
-C(=O)-(PEG)-C(=O)-;
-C(=O)-(PEG)-O-;
-C(=O)-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-(MCgluc)-;
-C(=O)-(PEG)-C(=O)-(MCgluc)-;
-C(=O)-(PEG)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(PEG)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
-C(=O)-(PEG)-N(R5)-;
-C(=O)-(PEG)-N(R5)-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-N+(R5)2-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-C(=O)-N(R5)CH(AA1)C(=O)-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-C(=O)-N(R5)CH(AA1)C(=O)-N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(PEG)-SS-(C1-C12アルキルジイル)-OC(=O)-;
-C(=O)-(PEG)-SS-(C1-C12アルキルジイル)-C(=O)-;
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-;
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)-C(=O);
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
-C(=O)-CH2CH2OCH2CH2-(C1-C20ヘテロアリールジイル)-CH2O-(PEG)-C(=O)-(MCgluc)-;
-C(=O)-CH2CH2OCH2CH2-(C1-C20ヘテロアリールジイル)-CH2O-(PEG)-C(=O)-(MCgluc)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;および
-(スクシンイミジル)-(CH2)m-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-
からなる群から選択されるリンカーであり;
PEPは、式:
R6は、-CH2O-C(=O)-および任意に
MCglucは、基:
アルキル、アルキルジイル、アルケニル、アルケニルジイル、アルキニル、アルキニルジイル、アリール、アリールジイル、カルボシクリル、カルボシクリルジイル、ヘテロシクリル、ヘテロシクリルジイル、ヘテロアリール、およびヘテロアリールジイルは、F、Cl、Br、I、-CN、-CH3、-CH2CH3、-CH=CH2、-C≡CH、-C≡CCH3、-CH2CH2CH3、-CH(CH3)2、-CH2CH(CH3)2、-CH2OH、-CH2OCH3、-CH2CH2OH、-C(CH3)2OH、-CH(OH)CH(CH3)2、-C(CH3)2CH2OH、-CH2CH2SO2CH3、-CH2OP(O)(OH)2、-CH2F、-CHF2、-CF3、-CH2CF3、-CH2CHF2、-CH(CH3)CN、-C(CH3)2CN、-CH2CN、-CH2NH2、-CH2NHSO2CH3、-CH2NHCH3、-CH2N(CH3)2、-CO2H、-COCH3、-CO2CH3、-CO2C(CH3)3、-COCH(OH)CH3、-CONH2、-CONHCH3、-CON(CH3)2、-C(CH3)2CONH2、-NH2、-NHCH3、-N(CH3)2、-NHCOCH3、-N(CH3)COCH3、-NHS(O)2CH3、-N(CH3)C(CH3)2CONH2、-N(CH3)CH2CH2S(O)2CH3、-NHC(=NH)H、-NHC(=NH)CH3、-NHC(=NH)NH2、-NHC(=O)NH2、-NO2、=O、-OH、-OCH3、-OCH2CH3、-OCH2CH2OCH3、-OCH2CH2OH、-OCH2CH2N(CH3)2、-O(CH2CH2O)n-(CH2)mCO2H、-O(CH2CH2O)nH、-OP(O)(OH)2、-S(O)2N(CH3)2、-SCH3、-S(O)2CH3、および-S(O)3Hから独立して選択される1つ以上の基で独立してかつ任意に置換されている)を有するアミノベンズアゼピン部分である)。
3. 下付き文字pが1から6の整数である、一面2の高分子支持化合物。
4. 高分子支持体がペプチドである、一面1~3のいずれか一つの高分子支持化合物。
5. 高分子支持体がヌクレオチドである、一面1~3のいずれか一つの高分子支持化合物。
7. 高分子支持体が脂質である、一面1~3のいずれか一つの高分子支持化合物。
8. 高分子支持体が抗体構築物である、一面1~3のいずれか一つの高分子支持化合物。
9. 高分子支持体がバイオポリマーである、一面1~3のいずれか一つの高分子支持化合物。
10. 高分子支持体がナノ粒子である、一面1~3のいずれか一つの高分子支持化合物。
12. PEPが式:
15. AA1およびAA2がH、-CH3、-CH(CH3)2、-CH2(C6H5)、-CH2CH2CH2CH2NH2、-CH2CH2CH2NHC(NH)NH2、-CH2CH(CH3)2、-CH2SO3H、および-CH2CH2CH2NHC(O)NH2から独立して選択される、一面1~13のいずれか一つの高分子支持化合物。
17. 各AA1およびAA2がGlcNAcアスパラギン酸、-CH2SO3H、および-CH2OPO3Hから独立して選択される、一面1~13のいずれか一つの高分子支持化合物。
22. R2およびR3がそれぞれC1-C8アルキルである、一面1~21のいずれか一つの高分子支持化合物。
23. R2およびR3がそれぞれ-CH2CH2CH3である、一面22の高分子支持化合物。
24. X2およびX3がそれぞれ結合であり、R2またはR3が-O-(C1-C12アルキル)である、一面1~21のいずれか一つの高分子支持化合物。
25. R2またはR3が-OCH2CH3である、一面24の高分子支持化合物。
-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-O-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-N(R5)C(=NR5)-N(R5)-*;
-(C1-C12アルキルジイル)-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-C(=NR5)N(R5)-*;
-(C2-C6アルキニルジイル)-N(R5)-*;および
-(C2-C6アルキニルジイル)-N(R5)C(=NR5)N(R5)-*
から選択され;
X2およびX3が結合であり、ここで、アスタリスク*がLの接続サイトを示す、一面1~21のいずれか一つの高分子支持化合物。
-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-N(R5)C(=NR5)N(R5)-*;
-(C6-C20アリールジイル)-S(=O)2-(C2-C20ヘテロシクリルジイル)-*;
-(C6-C20アリールジイル)-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C6-C20アリールジイル)-C(=O)-*;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C6-C20アリールジイル)-C(=O)-(C2-C20ヘテロシクリルジイル)-*;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-*;および
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-(C2-C20ヘテロシクリルジイル)-C(=O)NR5-(C1-C12アルキルジイル)-NR5-*
から選択され;
X1およびX4が結合であり、ここで、アスタリスク*がLの接続サイトを示す、一面1~25のいずれか一つの高分子支持化合物。
29. C6-C20アリールジイルがフェニルジイルであり、C2-C20ヘテロシクリルジイルがアゼチジンジイルである、一面28の高分子支持化合物。
32. C1-C20ヘテロアリールジイルがピリジンジイルであり、C2-C20ヘテロシクリルジイルがピペリジイルである、一面31の高分子支持化合物。
(式中、R1、R2、R3、およびR4は、独立してYまたはZであり、ここで、R1、R2、R3、およびR4の1つは、式:
各Zは独立して、水素であるかまたは式:
Uは、任意に存在して、CH2、C(=O)、CH2C(=O)、またはC(=O)CH2であり、
Aは、任意に存在して、NR10であるかまたは式:
R10およびWは独立して、水素、Ar1、または式:
Vは、任意に存在して、式:
J1およびJ2は独立して、CHまたはNであり、
m1、m2、およびm3は独立して、m1、m2、およびm3の少なくとも1つがゼロでない整数であることを除いて、0から25の整数であり、
n1、n2、n3、n4、n5、およびn6は独立して、0から10の整数であり、
t1およびt2は独立して、1から3の整数であり、
G1、G2、G3、およびG4は独立して、CH2、C(O)、CH2C(O)、C(O)CH2、または結合であり、
X1、X2、X3、およびX4は、それぞれ任意に存在して、独立して、O、NR7、CHR7、SO2、S、あるいは1つ若しくは2つのシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基であり、複数のシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基が存在するとき、該複数のシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基は、連結または縮合しており、ここで、連結したシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基は、結合または-CO-を通して連結しており、
R9は、水素、C1-C4アルキルであるか、または式:
R8は、独立して水素またはC1-C4アルキルであり、
Ar1およびAr2は独立して、1つ以上のハロゲン(例えば、フッ素、塩素、臭素、またはヨウ素)、ニトリル、ヒドロキシル、C1-C4アルキル基、若しくはそれらの組合せで任意に置換された、アリールまたはヘテロアリール基であり、
LMは、アミド、アミン、エステル、カルバメート、尿素、チオエーテル、チオカルバメート、チオカーボネート、およびチオ尿素から選択される官能基を含む連結部分であり、
rは、1から50の整数であり、
「MS」は、高分子支持体であり、
各波線
35. 下付き文字rが1から6の整数である、一面34の高分子支持化合物。
37. 高分子支持体がヌクレオチドである、一面33~35のいずれか一つの高分子支持化合物。
38. 高分子支持体が炭水化物である、一面33~35のいずれか一つの高分子支持化合物。
39. 高分子支持体が脂質である、一面33~35のいずれか一つの高分子支持化合物。
40. 高分子支持体が抗体構築物である、一面33~35のいずれか一つの高分子支持化合物。
42. 高分子支持体がナノ粒子である、一面33~35のいずれか一つの高分子支持化合物。
43. 高分子支持体が免疫チェックポイント阻害剤である、一面33~35のいずれか一つの高分子支持化合物。
44. 高分子支持体の、表2a、2b、および2c中に提供されるBzL-1からBzL-79のいずれか1つから選択されるアミノベンズアゼピン-リンカー化合物との接合によって製造される高分子支持化合物。
45. 一面1~44のいずれか一つに記載の複数の高分子支持化合物を含む組成物。
47. 高分子支持体に対するアミノベンズアゼピン部分の平均が約1から約10である、一面46の組成物。
48. 高分子支持体に対するアミノベンズアゼピン部分の平均が約1から約6である、一面47の組成物。
49. 高分子支持体に対するアミノベンズアゼピン部分の平均が約1から約4である、一面48の組成物。
50. 治療有効量の一面1~44のいずれか一つに記載の高分子支持化合物または一面45~49のいずれか一つに記載の組成物をそれを必要とする対象に投与することを含む、癌を治療する方法。
52. 癌を治療するための、一面1~44のいずれか一つに記載の高分子支持化合物または一面45~49のいずれか一つに記載の組成物の使用。
53. TLRの関与および/または活性についての化学アッセイのための、一面1~44のいずれか一項に記載の高分子支持化合物または一面45~49のいずれか一つに記載の組成物の使用。
54. 化学アッセイがTLR7および/またはTLR8の関与および/または活性についてである、一面53に記載の使用。
Claims (54)
- リンカーによって1つ以上のアミノベンズアゼピン部分に共有結合した高分子支持体を含み、式I:
を有する、高分子支持化合物またはその薬学的に許容される塩
(式中:
「MS」は、高分子支持体であり;
pは、1から50の整数であり;
Bzaは、式:
(R1、R2、R3、およびR4は、H、C1-C12アルキル、C2-C6アルケニル、C2-C6アルキニル、C3-C12カルボシクリル、C6-C20アリール、C2-C9ヘテロシクリル、およびC1-C20ヘテロアリールからなる群から独立して選択され、ここで、アルキル、アルケニル、アルキニル、カルボシクリル、アリール、ヘテロシクリル、およびヘテロアリールは、
-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-N(R5)2;
-(C3-C12カルボシクリル);
-(C3-C12カルボシクリル)-*;
-(C3-C12カルボシクリル)-(C1-C12アルキルジイル)-NR5-*;
-(C3-C12カルボシクリル)-(C1-C12アルキルジイル)-N(R5)2;
-(C3-C12カルボシクリル)-NR5-C(=NR5)NR5-*;
-(C6-C20アリール);
-(C6-C20アリール)-*;
-(C6-C20アリールジイル)-N(R5)-*;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)2;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-NR5-C(=NR5a)N(R5)-*;
-(C2-C20ヘテロシクリル);
-(C2-C20ヘテロシクリル)-*;
-(C2-C9ヘテロシクリル)-(C1-C12アルキルジイル)-NR5-*;
-(C2-C9ヘテロシクリル)-(C1-C12アルキルジイル)-N(R5)2;
-(C2-C9ヘテロシクリル)-NR5-C(=NR5a)NR5-*;
-(C1-C20ヘテロアリール);
-(C1-C20ヘテロアリール)-*;
-(C1-C20ヘテロアリール)-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C20ヘテロアリール)-(C1-C12アルキルジイル)-N(R5)2;
-(C1-C20ヘテロアリール)-NR5-C(=NR5a)N(R5)-*;
-C(=O)-*;
-C(=O)-(C2-C20ヘテロシクリルジイル)-*;
-C(=O)N(R5)2;
-C(=O)N(R5)-*;
-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)R5;
-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)N(R5)2;
-C(=O)NR5-(C1-C12アルキルジイル)-N(R5)CO2R5;
-C(=O)NR5-(C1-C12アルキルジイル)-N(R5)C(=NR5a)N(R5)2;
-C(=O)NR5-(C1-C12アルキルジイル)-NR5C(=NR5a)R5;
-C(=O)NR5-(C1-C8アルキルジイル)-NR5(C2-C5ヘテロアリール);
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-N(R5)-*;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-*;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-(C1-C12アルキルジイル)-N(R5)2;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-(C2-C20ヘテロシクリルジイル)-C(=O)NR5-(C1-C12アルキルジイル)-NR5-*;
-N(R5)2;
-N(R5)-*;
-N(R5)C(=O)R5;
-N(R5)C(=O)-*;
-N(R5)C(=O)N(R5)2;
-N(R5)C(=O)N(R5)-*;
-N(R5)CO2R5;
-NR5C(=NR5a)N(R5)2;
-NR5C(=NR5a)N(R5)-*;
-NR5C(=NR5a)R5;
-N(R5)-(C2-C5ヘテロアリール);
-O-(C1-C12アルキル);
-O-(C1-C12アルキルジイル)-N(R5)2;
-O-(C1-C12アルキルジイル)-N(R5)-*;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-*;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-N(R5)2;
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-NR5-*;および
-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-OH
から選択される1つ以上の基で独立してかつ任意に置換されており;
またはR2およびR3が一緒になって、5若しくは6員のヘテロシクリル環を形成し;
X1、X2、X3、およびX4は、結合、C(=O)、C(=O)N(R5)、O、N(R5)、S、S(O)2、およびS(O)2N(R5)からなる群から独立して選択され;
R5は、H、C6-C20アリール、C6-C20アリールジイル、C1-C12アルキル、およびC1-C12アルキルジイルからなる基から選択されるか、または2つのR5基が一緒になって、5若しくは6員のヘテロシクリル環を形成し;
R5aは、C6-C20アリールおよびC1-C20ヘテロアリールからなる群から選択され;
ここで、アスタリスク*は、Lの接続サイトを示し、R1、R2、R3、およびR4の1つは、Lに接続されており;
Lは、
-C(=O)-(PEG)-;
-C(=O)-(PEG)-C(=O)-;
-C(=O)-(PEG)-O-;
-C(=O)-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
-C(=O)-(PEG)-C(=O)N(R5)-(C1-C12アルキルジイル)-(MCgluc)-;
-C(=O)-(PEG)-C(=O)-(MCgluc)-;
-C(=O)-(PEG)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(PEG)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
-C(=O)-(PEG)-N(R5)-;
-C(=O)-(PEG)-N(R5)-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-N+(R5)2-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-C(=O)-N(R5)CH(AA1)C(=O)-(PEG)-C(=O)-(PEP)-;
-C(=O)-(PEG)-C(=O)-N(R5)CH(AA1)C(=O)-N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(PEG)-SS-(C1-C12アルキルジイル)-OC(=O)-;
-C(=O)-(PEG)-SS-(C1-C12アルキルジイル)-C(=O)-;
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-;
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-;
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)-C(=O);
-C(=O)-(C1-C12アルキルジイル)-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;
-C(=O)-CH2CH2OCH2CH2-(C1-C20ヘテロアリールジイル)-CH2O-(PEG)-C(=O)-(MCgluc)-;
-C(=O)-CH2CH2OCH2CH2-(C1-C20ヘテロアリールジイル)-CH2O-(PEG)-C(=O)-(MCgluc)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-;および
-(スクシンイミジル)-(CH2)m-C(=O)-(PEP)-N(R5)-(C1-C12アルキルジイル)-N(R5)C(=O)-(C2-C5モノヘテロシクリルジイル)-
からなる群から選択されるリンカーであり;
PEGは、式:-(CH2CH2O)n-(CH2)m-を有し;mは、1から5の整数であり、nは、2から50の整数であり;
PEPは、式:
(式中、AA1およびAA2は、アミノ酸側鎖から独立して選択されるか、またはAA1若しくはAA2および隣接する窒素原子が5員環プロリンアミノ酸を形成し、波線は、付着点を示し;
R6は、-CH2O-C(=O)-および任意に
で置換された、C6-C20アリールジイルおよびC1-C20ヘテロアリールジイルからなる群から選択される)を有し;
MCglucは、基:
(式中、qは、1から8であり、AAは、アミノ酸側鎖である)から選択され;
アルキル、アルキルジイル、アルケニル、アルケニルジイル、アルキニル、アルキニルジイル、アリール、アリールジイル、カルボシクリル、カルボシクリルジイル、ヘテロシクリル、ヘテロシクリルジイル、ヘテロアリール、およびヘテロアリールジイルは、F、Cl、Br、I、-CN、-CH3、-CH2CH3、-CH=CH2、-C≡CH、-C≡CCH3、-CH2CH2CH3、-CH(CH3)2、-CH2CH(CH3)2、-CH2OH、-CH2OCH3、-CH2CH2OH、-C(CH3)2OH、-CH(OH)CH(CH3)2、-C(CH3)2CH2OH、-CH2CH2SO2CH3、-CH2OP(O)(OH)2、-CH2F、-CHF2、-CF3、-CH2CF3、-CH2CHF2、-CH(CH3)CN、-C(CH3)2CN、-CH2CN、-CH2NH2、-CH2NHSO2CH3、-CH2NHCH3、-CH2N(CH3)2、-CO2H、-COCH3、-CO2CH3、-CO2C(CH3)3、-COCH(OH)CH3、-CONH2、-CONHCH3、-CON(CH3)2、-C(CH3)2CONH2、-NH2、-NHCH3、-N(CH3)2、-NHCOCH3、-N(CH3)COCH3、-NHS(O)2CH3、-N(CH3)C(CH3)2CONH2、-N(CH3)CH2CH2S(O)2CH3、-NHC(=NH)H、-NHC(=NH)CH3、-NHC(=NH)NH2、-NHC(=O)NH2、-NO2、=O、-OH、-OCH3、-OCH2CH3、-OCH2CH2OCH3、-OCH2CH2OH、-OCH2CH2N(CH3)2、-O(CH2CH2O)n-(CH2)mCO2H、-O(CH2CH2O)nH、-OP(O)(OH)2、-S(O)2N(CH3)2、-SCH3、-S(O)2CH3、および-S(O)3Hから独立して選択される1つ以上の基で独立してかつ任意に置換されている)を有するアミノベンズアゼピン部分である)。 - 下付き文字pが1から25の整数である、請求項1の高分子支持化合物。
- 下付き文字pが1から6の整数である、請求項2の高分子支持化合物。
- 高分子支持体がペプチドである、請求項1~3のいずれか一項の高分子支持化合物。
- 高分子支持体がヌクレオチドである、請求項1~3のいずれか一項の高分子支持化合物。
- 高分子支持体が炭水化物である、請求項1~3のいずれか一項の高分子支持化合物。
- 高分子支持体が脂質である、請求項1~3のいずれか一項の高分子支持化合物。
- 高分子支持体が抗体構築物である、請求項1~3のいずれか一項の高分子支持化合物。
- 高分子支持体がバイオポリマーである、請求項1~3のいずれか一項の高分子支持化合物。
- 高分子支持体がナノ粒子である、請求項1~3のいずれか一項の高分子支持化合物。
- 高分子支持体が免疫チェックポイント阻害剤である、請求項1~3のいずれか一項の高分子支持化合物。
- 各AA1およびAA2が天然に存在するアミノ酸の側鎖から独立して選択される、請求項1~13のいずれか一項の高分子支持化合物。
- AA1およびAA2がH、-CH3、-CH(CH3)2、-CH2(C6H5)、-CH2CH2CH2CH2NH2、-CH2CH2CH2NHC(NH)NH2、-CH2CH(CH3)2、-CH2SO3H、および-CH2CH2CH2NHC(O)NH2から独立して選択される、請求項1~13のいずれか一項の高分子支持化合物。
- 各AA1が-CH(CH3)2であり、AA2が-CH2CH2CH2NHC(O)NH2である、請求項15の高分子支持化合物。
- 各AA1およびAA2がGlcNAcアスパラギン酸、-CH2SO3H、および-CH2OPO3Hから独立して選択される、請求項1~13のいずれか一項の高分子支持化合物。
- Lが-C(=O)-(PEG)-または-C(=O)-(PEG)-C(=O)-である、請求項18~20のいずれか一項の高分子支持化合物。
- R2およびR3がそれぞれC1-C8アルキルである、請求項1~21のいずれか一項の高分子支持化合物。
- R2およびR3がそれぞれ-CH2CH2CH3である、請求項22の高分子支持化合物。
- X2およびX3がそれぞれ結合であり、R2またはR3が-O-(C1-C12アルキル)である、請求項1~21のいずれか一項の高分子支持化合物。
- R2またはR3が-OCH2CH3である、請求項24の高分子支持化合物。
- R2およびR3の1つが
-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-O-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-N(R5)C(=NR5)-N(R5)-*;
-(C1-C12アルキルジイル)-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-C(=NR5)N(R5)-*;
-(C2-C6アルキニルジイル)-N(R5)-*;および
-(C2-C6アルキニルジイル)-N(R5)C(=NR5)N(R5)-*
から選択され;
X2およびX3が結合であり、ここで、アスタリスク*がLの接続サイトを示す、請求項1~21のいずれか一項の高分子支持化合物。 - R1およびR4の1つが
-(C1-C12アルキルジイル)-N(R5)-*;
-(C1-C12アルキルジイル)-N(R5)C(=NR5)N(R5)-*;
-(C6-C20アリールジイル)-S(=O)2-(C2-C20ヘテロシクリルジイル)-*;
-(C6-C20アリールジイル)-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C6-C20アリールジイル)-C(=O)-*;
-(C6-C20アリールジイル)-(C1-C12アルキルジイル)-N(R5)-*;
-(C6-C20アリールジイル)-C(=O)-(C2-C20ヘテロシクリルジイル)-*;
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-*;および
-C(=O)NR5-(C1-C20ヘテロアリールジイル)-(C2-C20ヘテロシクリルジイル)-C(=O)NR5-(C1-C12アルキルジイル)-NR5-*
から選択され;
X1およびX4が結合であり、ここで、アスタリスク*がLの接続サイトを示す、請求項1~25のいずれか一項の高分子支持化合物。 - R1およびR4の1つが-(C6-C20アリールジイル)-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-N(R5)2および-(C6-C20アリールジイル)-S(=O)2-(C2-C20ヘテロシクリルジイル)-(C1-C12アルキルジイル)-OHから選択される、請求項1~27のいずれか一項の高分子支持化合物。
- C6-C20アリールジイルがフェニルジイルであり、C2-C20ヘテロシクリルジイルがアゼチジンジイルである、請求項28の高分子支持化合物。
- R1およびR4の1つが-C(=O)NR5-(C1-C20ヘテロアリールジイル)-(C2-C20ヘテロシクリルジイル)-C(=O)NR5-(C1-C12アルキルジイル)-NR5-Lである、請求項1~27のいずれか一項の高分子支持化合物。
- C1-C20ヘテロアリールジイルがピリジンジイルであり、C2-C20ヘテロシクリルジイルがピペリジイルである、請求項31の高分子支持化合物。
- 式III:
の高分子支持化合物、その薬学的に許容される塩、またはその第四級アンモニウム塩
(式中、R1、R2、R3、およびR4は、独立してYまたはZであり、ここで、R1、R2、R3、およびR4の1つは、式:
を有する、Yであり;
各Zは独立して、水素であるかまたは式:
から選択され;
Uは、任意に存在して、CH2、C(=O)、CH2C(=O)、またはC(=O)CH2であり、
Aは、任意に存在して、NR10であるかまたは式:
から選択され
R10およびWは独立して、水素、Ar1、または式:
であり
Vは、任意に存在して、式:
であり、
J1およびJ2は独立して、CHまたはNであり、
m1、m2、およびm3は独立して、m1、m2、およびm3の少なくとも1つがゼロでない整数であることを除いて、0から25の整数であり、
n1、n2、n3、n4、n5、およびn6は独立して、0から10の整数であり、
t1およびt2は独立して、1から3の整数であり、
G1、G2、G3、およびG4は独立して、CH2、C(O)、CH2C(O)、C(O)CH2、または結合であり、
X1、X2、X3、およびX4は、それぞれ任意に存在して、独立して、O、NR7、CHR7、SO2、S、あるいは1つ若しくは2つのシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基であり、複数のシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基が存在するとき、該複数のシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基は、連結または縮合しており、ここで、連結したシクロアルキルジイル、ヘテロシクロアルキルジイル、アリールジイル、またはヘテロアリールジイル基は、結合または-CO-を通して連結しており、
R9は、水素、C1-C4アルキルであるか、または式:
から選択され、
R8は、独立して水素またはC1-C4アルキルであり、
Ar1およびAr2は独立して、1つ以上のハロゲン(例えば、フッ素、塩素、臭素、またはヨウ素)、ニトリル、ヒドロキシル、C1-C4アルキル基、若しくはそれらの組合せで任意に置換された、アリールまたはヘテロアリール基であり、
LMは、アミド、アミン、エステル、カルバメート、尿素、チオエーテル、チオカルバメート、チオカーボネート、およびチオ尿素から選択される官能基を含む連結部分であり、
rは、1から50の整数であり、
「MS」は、高分子支持体であり、
各波線
は、付着点を表す)。 - 下付き文字rが1から25の整数である、請求項33の高分子支持化合物。
- 下付き文字rが1から6の整数である、請求項34の高分子支持化合物。
- 高分子支持体がペプチドである、請求項33~35のいずれか一項の高分子支持化合物。
- 高分子支持体がヌクレオチドである、請求項33~35のいずれか一項の高分子支持化合物。
- 高分子支持体が炭水化物である、請求項33~35のいずれか一項の高分子支持化合物。
- 高分子支持体が脂質である、請求項33~35のいずれか一項の高分子支持化合物。
- 高分子支持体が抗体構築物である、請求項33~35のいずれか一項の高分子支持化合物。
- 高分子支持体がバイオポリマーである、請求項33~35のいずれか一項の高分子支持化合物。
- 高分子支持体がナノ粒子である、請求項33~35のいずれか一項の高分子支持化合物。
- 高分子支持体が免疫チェックポイント阻害剤である、請求項33~35のいずれか一項の高分子支持化合物。
- 高分子支持体の、表2a、2b、および2c中に提供されるBzL-1からBzL-79のいずれか1つから選択されるアミノベンズアゼピン-リンカー化合物との接合によって製造される高分子支持化合物。
- 請求項1~44のいずれか一項に記載の複数の高分子支持化合物を含む組成物。
- 高分子支持体に対するアミノベンズアゼピン部分の平均が約0.01から約50である、請求項45の組成物。
- 高分子支持体に対するアミノベンズアゼピン部分の平均が約1から約10である、請求項46の組成物。
- 高分子支持体に対するアミノベンズアゼピン部分の平均が約1から約6である、請求項47の組成物。
- 高分子支持体に対するアミノベンズアゼピン部分の平均が約1から約4である、請求項48の組成物。
- 治療有効量の請求項1~44のいずれか一項に記載の高分子支持化合物または請求項45~49のいずれか一項に記載の組成物をそれを必要とする対象に投与することを含む、癌を治療する方法。
- 癌がTLR7および/またはTLR8アゴニズムによって誘導される炎症誘発性応答の影響を受けやすい、請求項50の方法。
- 癌を治療するための、請求項1~44のいずれか一項に記載の高分子支持化合物または請求項45~49のいずれか一項に記載の組成物の使用。
- TLRの関与および/または活性についての化学アッセイのための、請求項1~44のいずれか一項に記載の高分子支持化合物または請求項45~49のいずれか一項に記載の組成物の使用。
- 化学アッセイがTLR7および/またはTLR8の関与および/または活性についてである、請求項53に記載の使用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962861139P | 2019-06-13 | 2019-06-13 | |
US201962861117P | 2019-06-13 | 2019-06-13 | |
US62/861,139 | 2019-06-13 | ||
US62/861,117 | 2019-06-13 | ||
US202062963884P | 2020-01-21 | 2020-01-21 | |
US62/963,884 | 2020-01-21 | ||
PCT/US2020/037423 WO2020252254A1 (en) | 2019-06-13 | 2020-06-12 | Macromolecule-supported aminobenzazepine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022538773A true JP2022538773A (ja) | 2022-09-06 |
Family
ID=71409515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021573551A Pending JP2022538773A (ja) | 2019-06-13 | 2020-06-12 | 高分子支持アミノベンズアピン化合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220315537A1 (ja) |
EP (1) | EP3983080A1 (ja) |
JP (1) | JP2022538773A (ja) |
CA (1) | CA3143156A1 (ja) |
WO (1) | WO2020252254A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Her2を標的とする免疫結合体 |
BR112022007719A2 (pt) | 2019-10-25 | 2022-07-12 | Bolt Biotherapeutics Inc | Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado |
WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
TW202216211A (zh) | 2020-07-01 | 2022-05-01 | 美商希沃爾拜克治療公司 | 抗asgr1抗體共軛物及其用途 |
KR20230051189A (ko) * | 2020-08-13 | 2023-04-17 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 피라졸로아제핀 면역접합체, 및 그의 용도 |
CN116744978A (zh) * | 2020-12-11 | 2023-09-12 | 博尔特生物治疗药物有限公司 | 抗her2免疫缀合物及其用途 |
WO2022125908A1 (en) * | 2020-12-11 | 2022-06-16 | Bolt Biotherapeutics, Inc. | Anti-pd-l1 immunoconjugates, and uses thereof |
US20220195066A1 (en) * | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
WO2022125915A1 (en) * | 2020-12-11 | 2022-06-16 | Bolt Biotherapeutics, Inc. | Anti-her2 immunoconjugates, and uses thereof |
JP2024501453A (ja) * | 2020-12-11 | 2024-01-12 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗ceaイムノコンジュゲート、及びそれらの使用 |
CA3212926A1 (en) * | 2021-03-26 | 2022-09-29 | Gary Brandt | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
JP2024512056A (ja) * | 2021-03-26 | 2024-03-18 | ボルト バイオセラピューティクス、インコーポレーテッド | 2-アミノ-4-カルボキサミド-ベンゾアゼピン免疫複合体、及びその使用 |
WO2023076599A1 (en) | 2021-10-29 | 2023-05-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
WO2023109944A1 (zh) * | 2021-12-16 | 2023-06-22 | 映恩生物制药(苏州)有限公司 | Tlr调节剂及其用途 |
WO2023154318A1 (en) * | 2022-02-09 | 2023-08-17 | Bolt Biotherapeutics, Inc. | Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof |
WO2023154302A1 (en) * | 2022-02-09 | 2023-08-17 | Bolt Biotherapeutics, Inc. | Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190336615A1 (en) * | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
US10239862B2 (en) * | 2017-03-15 | 2019-03-26 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
JP2021506827A (ja) * | 2017-12-15 | 2021-02-22 | シルバーバック セラピューティックス インコーポレイテッド | 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート |
US20200113912A1 (en) * | 2018-09-12 | 2020-04-16 | Silverback Therapeutics, Inc. | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates |
CA3112545A1 (en) * | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
WO2020056194A1 (en) * | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
-
2020
- 2020-06-12 EP EP20735747.6A patent/EP3983080A1/en active Pending
- 2020-06-12 JP JP2021573551A patent/JP2022538773A/ja active Pending
- 2020-06-12 CA CA3143156A patent/CA3143156A1/en active Pending
- 2020-06-12 WO PCT/US2020/037423 patent/WO2020252254A1/en active Application Filing
- 2020-06-12 US US17/618,729 patent/US20220315537A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3983080A1 (en) | 2022-04-20 |
CA3143156A1 (en) | 2020-12-17 |
WO2020252254A1 (en) | 2020-12-17 |
US20220315537A1 (en) | 2022-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022538773A (ja) | 高分子支持アミノベンズアピン化合物 | |
JP2022537158A (ja) | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 | |
KR20220077131A (ko) | 아마이드-연결된 아미노벤즈아제핀 면역접합체 및 이의 용도 | |
WO2021081402A1 (en) | Macromolecule-supported thienoazepine compounds, and uses thereof | |
US20230338571A1 (en) | Thienoazepine immunoconjugates, and uses thereof | |
CN114630684A (zh) | 氨基喹啉化合物、免疫缀合物及其用途 | |
KR20230118149A (ko) | 항-pd-l1 면역접합체, 및 그의 용도 | |
JP2023552792A (ja) | 抗her2免疫複合体、及びその使用 | |
KR20230118148A (ko) | 암 치료에 유용한 하나 이상의 8-het-2-아미노벤자제핀유도체에 대한 접합에 의해 연결된 항-cea 항체를 포함하는 면역접합체 | |
CN115209920A (zh) | 噻吩并氮呯免疫缀合物及其用途 | |
WO2023154302A1 (en) | Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses | |
WO2023154318A1 (en) | Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20220404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220404 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20220712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220712 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20220715 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240312 |